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4 Introduction and aim of the study 
It is well known that high density lipoproteins (HDL) and low density lipoproteins 
(LDL) play a crucial role in regulation of platelet function and that circulating HDL 
cholesterol is reducing the risk of atherosclerosis. It is important to understand the mo-
lecular and cellular mechanisms that lead to the development of atherosclerosis for iden-
tifying strategies to limit disease progression before it leads to clinical consequences. 
HDL inclose several subclasses, mainly HDL2 and HDL3, which diversify in size and 
composition and these subclasses exert different functions in the body. We aimed to 
evaluate differences in their effects on P-selectin expression in platelets and additionally 
we wanted to detect the influence of HDL on phosphorylated VASP (VASP-P). In sum-
mary, within this diploma thesis evaluations of the impact of native and hypochlorite 
modified HDL2 and HDL3 subclasses on degranulation and on the intracellular degree 
of VASP-P in human blood platelets were performed. Hypochlorite was used because of 
its proven in vivo relevance. It is formed in vivo by myeloperoxidase (MPO) from acti-
vated neutrophiles and monocytes. Moreover, MPO is present in human atherosclerotic 
lesions (Daugherty et al. 1994;Malle et al. 2006a;Marsche et al. 2008). Furthermore, the 
relevance of 2-Chlorohexadecanal (2-ClHDA) on platelet function was determined, be-
cause studies show its importance in mediating the inhibition of vasculoprotective nitric 
oxide synthase (NOS) in endothelial cells (Marsche et al. 2004). 2-ClHDA is produced 
in consequence of myocardial infarction (Thukkani et al. 2005) and findings also show 
that 2-ClHDA is able to manipulate neutrophil recruitment in vitro (Thukkani et al. 
2002). Trials were carried out with FACS analysis to identify the differences between 
HDL2 and HDL3 in their interaction with human platelets. 
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5 Literature overview 
5.1 Clinical picture of atherosclerosis 
At present time, cardiovascular disease is the main cause for death and illness in devel-
oped countries. It will emerge as an outstanding health problem worldwide in future 
(Libby 2002). Various research studies tried to investigate the initiating factors that lead 
to atherosclerosis. Ross formulated the response to injury hypothesis, which first stated 
that endothelial denudation represents the first step of atherosclerosis. A more recent 
version says that endothelial dysfunction, and not denudation is the key event (Ross 
1999). Other studies indicate that retention of lipoproteins within the vessel wall is initi-
ating atherosclerosis, from which the response to retention hypothesis followed 
(Williams and Tabas 1995). In 1989, Steinberg et al. proposed the oxidative modifica-
tion hypothesis, which was supported by many studies subsequently. This hypothesis 
points out modified lipoproteins in the vascular wall, built as a consequence of oxidative 
stress, as the crucial factor (Nakajima et al. 2006). These different hypotheses still 
evoke discussions, but one can definitely say that oxidative stress, lipoproteins and 
platelets play a pivotal role in the development of atherosclerosis. Atherosclerosis is a 
form of chronic inflammation resulting from interaction between modified lipoproteins, 
monocyte derived macrophages, T-cells, and the endothelium (Glass and Witztum 
2001). It is not simply a disease, but rather a process contributing to the pathogenesis of 
various diseases, which in fact is a protective response to insults to the endothelium and 
smooth muscle cells of the arterial wall (Ross 1993). 
 
5.1.1 Development 
Epidemiologic studies identify genetic and environmental risk factors for the develop-
ment of atherosclerosis. Elevated levels of serum cholesterol are proven to lead to this 
development in humans and experimental animals, even in the absence of other known 
risk factors (Glass and Witztum 2001). Oxidative stress and free radicals, caused by 
cigarette smoking, hypertension, diabetes mellitus, genetic alterations, elevated plasma 
homocysteine concentrations, and infectious microorganisms can cause endothelial dys-
function and hence are ranked among risk factors. Different phases in the chronic in-
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flammatory process in the artery are noticeable (Ross 1999). At the beginning the 
atherosclerotic process is a protective response to an injury to the endothelium and 
smooth muscle cells of the arterial wall (Noll 1998). Under ordinary circumstances, the 
normal arterial endothelium is in contact with the flowing blood, but resists adhesion of 
leucocytes including blood monocytes. If endothelial cells are activated by inflamma-
tion, their expression of various leukocyte adhesion molecules is enhanced. The mono-
cytes adhere to the activated endothelial layer and then diapedese between intact endo-
thelial cells to reach the tunica intima and innermost layer of the arterial wall. 
Monocytes differentiate within the intima into tissue macrophages. Macrophages in the 
atheroma express scavenger receptors that bind oxidized lipoprotein particles (Libby 
2002). Oxidized LDL lose their specificity for the apo-B receptor during their modifica-
tion and thus are taken up by scavenger receptors that are found on macrophages. This 
process converts the macrophage into a foam cell, which is the hallmark of the arterial 
lesion. Growth factors, cytokines and other factors are expressed by foam cells. Cyto-
kines stimulate endothelial cells to express adhesion molecules, which result in the ad-
herence of more blood monocytes to the endothelial cell layer. The accumulation of 
foam cells and the proliferation of smooth muscle cells in response to growth factors 
released from macrophages lead to the formation of fatty streaks. This lesion is widely 
regarded as precursor of the mature atherosclerotic plaque (Barter et al. 2003a). This 
earliest type of lesion is pure inflammatory and is only made up of monocyte derived 
macrophages and T-lymphocytes (Ross 1999). Macrophages congregate in a central 
core in the typical atherosclerotic plaque. When the plaque ruptures, blood gets in con-
tact with the potent procoagulant protein tissue factor, which is another macrophage 
product (Libby 2002). 
 
5.1.2 Clinical consequences 
Plaque rupture and thrombosis are considerable complications of advanced lesions that 
result in unstable coronary syndromes or myocardial infarctions (Falk et al. 1995). Gen-
erally large and medium sized elastic and muscular arteries are affected by lesions of 
atherosclerosis and these lesions can lead to ischemia of the heart, brain, or extremities, 
resulting in infarction. Myocardial infarction often occurs after erosion or uneven thin-
ning and rupture of the fibrous cap, which is situated at lesion where macrophages enter, 
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accumulate, are activated, and where apoptosis may occur. Macrophage accumulation 
may be associated with increased plasma concentrations of both fibrinogen and C-
reactive protein. Because of this, markers of inflammation may represent early signs of 
atherosclerosis. Degradation of the fibrous cap is the consequence of elaboration of 
metalloproteinases, such as collagenases, elastases, and stromelysins. Plaque instability 
and immune response are promoted by activated T cells possibly through stimulation of 
metalloproteinase production by macrophages in lesions. Further changes are the pro-
duction of tissue-factor and other hemostatic factors (Ross 1999). 
 
5.1.3 Atherosclerosis in context of HDL 
There is increasing evidence that enhanced HDL levels diminish cardiovascular risk 
(Castelli 1996;Lamarche et al. 1997;Watts and Burnett 2004). HDL have protective 
effects against atherosclerosis and cardiovascular disease. These effects are mediated by 
enhanced reverse cholesterol transport and by direct antiatherosclerotic mechanisms. 
Epidemiological studies reveal that a 0.026 mmol/L increase in plasma HDL reduces 
the risk of coronary heart disease (CHD) by 2% in men and by 3% in women. These 
effects of HDL are independent of triglyceride and LDL concentrations. Another study 
shows that a 0.15 mmol/L increase in plasma HDL is associated with an 11% decrease 
in CHD. Significant data also demonstrate that HDL have intrinsic antiatherosclerotic 
properties, such as anti-inflammatory (Chrysohoou et al. 2007), antioxidant, antimitotic, 
anticoagulant, antiaggregatory, and profibrinolytic properties (Watts and Burnett 2004). 
In contrast, LDL are one of the most powerful and independent risk factors for CHD 
(Castelli 1996). According to results of several studies it is considered positive to have a 
high concentration of HDL in plasma together with a low level of LDL. In contrast, 
studies show that patients with almost total deficiencies of HDL are not more in danger 
of atherothrombotic cardiovascular disease than control subjects. An explanation could 
be that the relationship between the concentration of HDL and atherothrombotic cardio-
vascular disease might only be secondary to alterations in the metabolism of triglyceride 
rich lipoproteins or that these HDL deficiencies usually occur with a concomitant con-
siderable reduction in LDL (Sastre et al. 2002). 
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5.2 Human blood platelets 
Platelets play an important role in atherosclerosis because platelet adhesion and throm-
bosis are omnipresent in the initiation and generation of atherosclerotic lesions. They 
are important for vascular integrity in the absence of injury and protecting against spon-
taneous hemorrhage. Moreover, they can stick to dysfunctional endothelium and upon 
activation platelets release their granules, which contain cytokines and growth factors. 
Arachidonic acid liberated by activated platelets can be converted into prostaglandins 
such as thromboxane A2, which is one of the most potent vasoconstricting and platelet 
aggregating substances known or into leukotrienes, which can amplify the inflammatory 
response. These factors and also thrombin may account for the migration and prolifera-
tion of smooth muscle cells and monocytes. Activated platelets can accumulate on the 
walls of arteries and recruit additional platelets into an expanding thrombus (Ross 
1999). 
 
5.2.1 Structure 
Human platelets are the smallest cells in the blood and they are built by fragmentation 
of megakaryocytes. Platelets also enclose 2 unique organelles, the alpha- and dense 
granules and have a life span of 7 to 10 days. Only a few are consumed in the process of 
hemostasis, the others circulate until they are removed by phagocytic cells. The normal 
blood platelet count of a healthy human is 150 000 to 450 000 cells/mm3. Platelets play 
a crucial role in thrombosis, hemorrhage, inflammation, tumor growth and defence, as 
well as antimicrobial activity (Chaer et al. 2006). 
 
5.2.2 Signal transduction 
The most important role of platelets is the process of primary hemostasis that is respon-
sible for initiation and perpetuation of the hemostatic cascade. Primary hemostasis is 
characterized by vascular contraction, platelet adhesion and formation of a soft aggre-
gate plug. It begins immediately after endothelial disruption. Secondary hemostasis is 
defined as the formation of fibrin and is responsible for stabilizing the soft clot and for 
maintaining vasoconstriction (Özüyaman 2003). 
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5.2.2.1 Platelet activation 
Surface receptors regulate many functions and thereby control platelet activity. Various 
agonists and adhesive proteins have an impact on platelet receptors. In general, after 
stimulation of platelet receptors, different processes are activated (Freedman 2005). 
These processes are shape change, aggregation, secretory processes, and liberation of 
arachidonic acid. Arachidonic acid is rapidly converted into prostaglandins and lipoxy-
genase products (Willoughby et al. 2002). Adhesion occurs when circulating von Wille-
brand factor (vWf) attaches to the subendothelium. Glycoproteins (GPs) on the platelet 
surface adhere to the vWf. This results in an increase of intracellular calcium (Ca2+) 
through tyrosine kinases and in an activation of the GP IIb/IIIa receptor (Özüyaman 
2003). The interaction between platelet activating agonists, such as adenosine diphos-
phate (ADP), epinephrine, collagen, thrombin, serotonin, platelet activating factor, and 
their receptors evoke rapid mobilization of signalling molecules within the platelet. 
These signalling molecules are in particular Ca2+, diacylglycerol, and inositol 1.4.5-
trisphosphate, which are sufficient to activate and conclude shape change and aggrega-
tion responses (Willoughby et al. 2002). 
 
5.2.2.1.1 Transmembrane domain receptors 
Thrombin receptors 
There are several protease activated receptors (PAR) like PAR-1 and PAR-4 on platelets. 
A clear mechanism of activation including a specific cleavage of the N-terminus acting 
as a ligand to the receptor is characteristic for the PAR class of receptors (Freedman 
2005). The GPIb-IX complex is also ranked among this family and thrombin stimula-
tion of human platelets results in its reduced surface expression (Kovacsovics and 
Hartwig 1996). 
 
ADP receptors 
ADP plays a crucial role in erythrocytes and endothelial cells. ADP is an important fac-
tor in hemostasis, thrombus formation, and vascular occlusion because it leads to plate-
let aggregation. ADP is secreted from the dense granules of stimulated platelets and is 
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able to amplify platelet aggregation. Furthermore, ADP evokes a rapid influx of external 
Ca2+ and mobilizes Ca2+ from intracellular stores. Attenuation of the inhibition of ade-
nyl cyclase in platelets is also initiated by ADP. The transduction of ADP induced sig-
nals is possible through binding of ADP to purinergic receptors on the platelet surface. 
ADP receptors can be classified as P2X1, P2Y1, and P2Y12 (Freedman 2005). 
 
5.2.2.1.2 Integrins 
Glycoprotein IIb/IIIa 
GP IIb/IIIa is an αIIbβ3 integrin and is only expressed on platelets (Freedman 2005). 
Every inactive platelet has approximately 80 000 copies of GP IIb/IIIa on its surface and 
on its α-granule membranes, which are dislocated to the surface after activation. Previ-
ous to activation, GP IIb/IIIa within the α-granule membranes is not on the surface 
(Özüyaman 2003). The GP IIb/IIIa is characterized by an inactive conformation and 
functions as a low-affinity adhesion receptor for fibrinogen in inactivated platelets. Af-
ter stimulation intracellular bridges between platelets are formed by interactions be-
tween fibrinogen and GP IIb/IIIa (Freedman 2005). The affinity between this complex 
and fibrinogen and the number of receptors on the platelet surface are increased through 
thrombotic stimuli (Özüyaman 2003). GP IIb/IIIa mediates outside-in signalling and 
initiates intracellular signalling that further stabilizes the aggregate immediately after 
binding of fibrinogen. Some consequences of activation of the GP IIb/IIIa complex are 
Ca2+ mobilization, tyrosine phosphorylation, activation of phosphoinositide metabolism, 
and cytoskeletal reorganisation. These events change platelet aggregation from a re-
versible to an irreversible process. Platelet aggregation is completely inhibited by 
blockade of 80% of the surface GP IIb/IIIa receptors (Freedman 2005). 
 
Glycoprotein Ia/IIa 
This collagen receptor is an α2β1 integrin. Damaged blood vessels expose the subendo-
thelium to the bloodstream and thus platelets therein react with collagen. Platelets ad-
here to the damaged surface and form aggregates. Collagen has a strong ability to in-
duce platelet adhesion and aggregation and there is a high content of collagen in the 
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subendothelium. A cascade of reactions is initiated after activation, which is important 
for activating the integrins and adhesive proteins. Integrin α2β1 exists in three different 
conformations, such as a resting, non-active conformation (R0) having no affinity for 
soluble collagen and activated states R1 and R2, where R2 has higher affinity for solu-
ble collagen than R1. ADP is secreted by other activated platelets and converts R0 to 
R1. Platelets release ADP due to low agonist concentrations. In platelets activated by a 
high agonist concentration also other systems are activated, such as protein kinase-C, 
phosphatidyl inositol 3-kinase, and protein tyrosine kinase. These signals result in the 
conversion of the R1 state activated integrin α2β1 to the further activated form R2 (Jung 
and Moroi 2000). 
 
5.2.2.2 Platelet secretion 
Additional circulating platelets are activated by substances released from stimulated and 
aggregated platelets. Thereafter a thrombus is formed by fibrinogen bridging with the 
adherent platelets. The process of attracting additional platelets is called recruitment. 
Impairment of this process affects normal hemostasis, thrombosis and vascular remodel-
ling. Synthesis of thromboxane (TXA2) is stimulated by platelet activation and causes 
recruitment. Arachidonic acid is released from membrane phospholipids by phospholi-
pase A2 and C after platelet activation. Cyclooxygenase converts arachidonic acid to 
TXA2 that binds to platelet thromboxane receptors and thereby further activates plate-
lets what leads to activation of phospholipase C and liberation of intracellular Ca2+. 
Both ADP and TXA2 participate in a positive feedback loop that leads to platelet aggre-
gation and recruitment. Platelets also release antithrombotic substances that may pro-
vide negative feedback for thrombus formation like nitric oxide (NO). Platelet function 
is inhibited by stimulating soluble guanylyl cyclase to produce cyclic guanosine mono-
phosphate (cGMP), which results in the stimulation of cGMP dependent protein kinase 
(Freedman 2005). 
 
 16 
5.2.2.3 Thrombus stability 
The final phase of thrombus formation occurs after the receptors have been desensi-
tized. This phase is essential for stabilising the platelet thrombus and for preventing 
premature disaggregation. For thrombus stability a sustained ligand binding to activated 
GP IIb/IIIa may be required. This binding is probably influenced by Ca2+.The release of 
Ca2+ is induced by continuous stimulation of specific signalling pathways. PI3-kinase 
inhibition causes progressive reversal of aggregation after initial aggregation (Freedman 
2005;Goto et al. 2006). 
 
5.2.3 Endogenous influences on platelet function 
5.2.3.1 Prostacyclin and VASP 
Eicosanoids are generated from arachidonic acid by cyclooxygenase in endothelial cells 
and platelets. Endothelial cells include prostacyclin synthetase, which converts 
endoperoxides to prostacyclin (PGI2). Another tissue hormone of the body is PGE1, 
which also shows platelet stabilizing effects (Chang et al. 1990). A chemically synthe-
sized form of PGE1 was used within our project. PGI2 stimulates adenylyl cyclase and is 
linked to a specific receptor on the surface of platelets. This leads to an increase of 
cAMP and results in Ca2+ reuptake by the dense tubular system (Best et al. 1977;Walter 
et al. 1993). Both PGE1 and PGE2 independently increase platelet cyclic AMP 
(McDonald and Stuart 1974). In consequence of this reuptake, intracellular Ca2+ content 
decreases and thus phosphorylation of vasodilator stimulated phosphoprotein (VASP) is 
increased and stabilized. VASP is a major substrate of protein kinase A and is a 46/50 
kDa phosphoprotein, which is phoshorylated dependent on cGMP and cAMP dependent 
protein kinases. Three phosphorylation sites, Ser157, Ser239 and Thr278, have been 
identified. The phosphorylation of VASP (VASP-P) closely correlates with the inhibition 
of platelets, in particular with the inhibition of the fibrinogen bond to GP IIb/IIIa and 
thereby is used as an indicator for inhibition of platelets (Halbrugge et al. 1990;Horstrup 
et al. 1994). Due to these mechanisms PGI2 inhibits platelet activation, platelet granule 
secretion, platelet aggregation, and the development of platelet procoagulant activities, 
in part through inhibition of release of P-selectin (Kroll and Schafer 1989;Willoughby et 
al. 2002). 
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5.2.3.2 Nitric oxide 
NO is released by the intact endothelium and is mostly involved in the regulation of 
vascular tone and has antithrombotic properties. NO is able to decrease vascular smooth 
muscle tone and to inhibit platelet responses, like platelet adhesion, platelet granule se-
cretion, and platelet aggregation (Freedman et al. 1997;Loscalzo 2001). It prevents 
thrombosis and inhibits the normal activation dependent increase in the expression of 
platelet surface GPs including P-selectin and the integrin GP IIb/IIIa complex. Further-
more, NO decreases the oxidation of arachidonate and inhibits the agonist dependent 
increase in platelet cytosolic free Ca2+ (Freedman 2005). NO activates soluble guanylyl 
cyclase, which results in an increase in cGMP production. Furthermore, this leads to 
phoshorylation of VASP through cGMP dependent proteinkinase (Eigenthaler et al. 
1999;Lawrence and Pryzwansky 2001). Activation of cGMP dependent protein kinase 
also results in phosphorylation of Ca2+ transporters that decrease intracellular Ca2+ con-
centration. NO is produced during platelet aggregation and platelets themselves have 
constitutive and inducible NOS (cNOS and iNOS). Platelet derived NO pool also limits 
platelet recruitment to the growing platelet thrombus, possibly limiting the selfamplifi-
cation of platelet thrombus formation in vivo (Freedman et al. 1997). 
 
5.2.4 Interaction of platelets and lipoproteins 
Platelets and lipoproteins are intimately connected with the pathogenesis of a wide vari-
ety of diseases, including atherosclerosis, thrombosis, and coronary heart disease. Re-
sults of studies suggest a direct relationship between plasma lipoproteins and the hemo-
static function of platelets. Data also show that platelet hypersensitivity to stimulation is 
associated with increased cholesterol and that lipoproteins can augment the aggregation 
response of platelets. Thrombin-induced platelet aggregation is decreased by HDL and 
increased by LDL (Curtiss and Plow 1984). Platelets exposed to oxidized LDL show 
immediate platelet shape change and pseudopodia formation that increase adhesion of 
platelets to endothelial cells under flow conditions (Dardik et al. 2000). Collagen-
stimulated platelets induce LDL modification, which is noticeable by increased conju-
gated dienes and lysophosphatidylcholine formation, enhanced electrophoretic mobility, 
Apo B-100 degradation, and monocyte LDL uptake. It is also shown a reduction of vi-
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tamin E in LDL induced by activated platelets. There is evidence that platelets modify 
LDL via nicotinamide adenine dinucleotide phosphate (NADPH) oxidase mediated oxi-
dative stress. This phenomenon could be regulated by arachidonic acid liberation. It is 
suggested that platelets play a role in favouring LDL accumulation within atheroscle-
rotic plaque (Carnevale et al. 2007). Studies also report that very low density lipopro-
teins (VLDL) and remnant lipoproteins are able to activate platelets and the coagulation 
pathway and they can support the assembly of the prothrombinase complex. VLDL in-
crease the expression and activity of the plasminogen activator inhibitor-1 gene and 
plasminogen activator inhibitor-1 antigen in platelets. This process is characterized by 
platelet aggregation and clot formation (Olufadi and Byrne 2006). 
 
5.3 Human plasma lipoproteins 
5.3.1 Plasma lipoprotein subclasses 
Lipoproteins are divided into four major classes based on their chemical composition 
and their physical characteristics, like electrophoretic mobility, density, and diameter. 
One can distinguish between chylomicrons, VLDL, LDL, and HDL (McPherson et al. 
2007). HDL particles are further subdivided into HDL2 and HDL3. Apart from the pre-
dominant HDL2 and HDL3 fractions, there also exists a subclass called HDL1, a very 
minor fraction in humans, less dense than HDL2 (Assmann and Schriewer 1980). 
 
5.3.2 Classification of HDL 
There exist various techniques to subfractionate HDL, including precipitation, 
electrophoresis, affinity chromatography, and ultracentrifugation. Within my diploma 
thesis ultracentrifugation was employed, which is the most often used method 
(McPherson et al. 2007). HDL can also be classified according to their apolipoprotein 
content. ApoA-I is quantitatively the most abundant protein in HDL, followed by apoA-
II. HDL are classified in HDL with apoA-I and without apoA-II, HDL with apoA-I and 
with apoA-II, and HDL with apoA-II and without apoA-I. HDL populations can also be 
divided according to their electrophoretic mobility in agarose gels. These are classified 
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as α, pre-β and γ HDL. Separation for size by non denaturing gel electrophoresis in 
polyacrylamide gradient gels is possible. The populations obtained by this method are 
similar to those obtained by ultracentrifugation and are called (from smaller to greater 
size) HDL3c, HDL3b, HDL3a, HDL2a and HDL2b (Skinner 1994). 
 
5.3.3 Metabolic pathway of HDL 
The inside of HDL is made up of hydrophobic lipids such as cholesteryl esters (CEs) 
and triglycerides (TG), surrounded by an outer shell in which free cholesterol is inter-
spersed with phospholipids, and the surface contains mostly apolipoproteins (Watts and 
Burnett 2004). The formation of HDL2 from HDL3 is continual and reversible. This is 
necessary for transport of cholesterol, of other lipids from extrahepatic cells and of 
catabolized triglyceride rich lipoproteins. Hepatic lipase converts HDL2 to HDL3 and is 
inhibited by estrogen and stimulated by androgens. Because of this, men have lower 
HDL2 levels than women (Nestel 1987). The average HDL cholesterol plasma level is 
55mg/dl for men and 65mg/dl for women (Kleuser 2007). ApoA-I and apoA-II are syn-
thesized more in women than in men. HDL turnover is also influenced by nutrition. 
ApoA-I and HDL2 are increased by carbohydrates, whilst synthesis is impeded by poly-
unsaturated fatty acids. Low fat and low cholesterol diets primarily result in lower HDL 
levels. Disorders such as alcoholic liver disease or Tangier disease can change HDL 
composition and force HDL removal (McPherson et al. 2007;Nestel 1987). The enzyme 
lecithin cholesterol acyltransferase (LCAT) accounts for conversion of HDL3 in HDL2. 
LCAT partially re-esterifies cholesterol. The enzyme cholesteryl ester transfer protein 
(CEPT) facilitates the transport of CEs, formed by the LCAT reaction, and TG between 
the lipoproteins. CEs can also be delivered to the liver for biliary secretion or reutiliza-
tion during lipoprotein assembling. However, not only phospholipids, but also apoA-I is 
involved in the process of removing cellular cholesterol, where distinct regions within 
apoA-I play an important role (Oram and Yokoyama 1996). 
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5.3.4 Apolipoproteins in HDL 
5.3.4.1 ApoA-I 
68% of HDL protein is made up of apoA-I, which is synthesized in liver and intestine, is 
composed of 243 amino acids and its molecular weight is 28 kDa. Zones of the α-helical 
properties, called amphipathic helices, can interact with phospholipids because they are 
formed by one hydrophobic and one hydrophilic side. The hydrophobic side is in con-
tact with the aliphatic chains of fatty acids. The hydrophilic part is in contact with the 
aqueous medium and interacting with the most polar region of phospholipids and with 
free cholesterol. Pre-pro-apoA-I, which is the precursor form, is characterized by high 
molecular weight. It is converted into pro-apoA-I after passing to cytoplasm. In the 
bloodstream and lymph, it is converted into the mature protein through the action of a 
plasmatic converter enzyme. The deficiency of apoA-I is associated with HDL defi-
ciency. There exist various models of apoA-I structures in nascent discoidal HDL. The 
spheroidal particles of HDL contain 2 to 4 molecules of apoA-I. Their structure is pre-
sumably similar to that of discoidal HDL. ApoA-I plays a cardinal role in the first steps 
of the efflux of cholesterol from cells and it is the cofactor of the enzyme LCAT (Sastre 
et al. 2002). 
 
5.3.4.2 ApoA-II 
Plasma concentration of apoA-II in normolipaemic individuals is, on average, 33-35 
mg/dl. ApoA-II constitutes approximately 20% of HDL protein and thus is the second 
most abundant HDL apolipoprotein. It is synthesized in the liver and the percentage of 
α-helix in apoA-II is 62% which has a closer affinity for lipid monolayers than that of 
apoA-I. This is the reason why apoA-I can be displaced from the HDL surface by an 
excess of apoA-II (Sastre et al. 2002). Results of studies show that apoA-II levels in 
plasma are mostly regulated by apoA-II production. In contrast, apoA-I levels are con-
trolled by apoA-I catabolism (Ikewaki et al. 1995). Different findings demonstrate that 
apoA-II either activates or inhibits the action of hepatic lipase and CETP. Results also 
show that apoA-I lipid complexes can serve as substrates for LCAT and apoA-II might 
not (Forte et al. 1995). Overexpression studies of apoA-II have not, however, consis-
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tently reported favourable effects on atherosclerosis in various experimental models 
(Watts and Burnett 2004). 
 
5.3.4.3 Apo-E 
The concentration of human apo-E in plasma is comparatively low with 3-6 mg/dl 
(Mahley et al. 1984), this is approximately 1-2% of total apolipoproteins and almost 
half can disappear during isolation of lipoproteins by ultracentrifugation. Most of the 
characteristics of apo-E are not related to a function in HDL. The existence of pre-β 
migrating HDL is interesting because it contains apo-E and seems to be able to induce 
the early steps of reverse transport of cholesterol from cell membranes to plasma. There 
exist apo-E polymorphisms, which could also influence reverse cholesterol transport. 
Furthermore, the presence of apo-E in HDL is related to the effectiveness of the transfer 
of HDL cholesterol esters to the SR-BI receptor (Arai et al. 1999). Studies reveal that 
apo-E shows a potent, but not unique effect in HDL, which acts inhibitory on platelets 
(Higashihara et al. 1991a). Apo-E acts as a receptor ligand and plays a role in immuno-
modulation and nerve regeneration (Schiele et al. 2000). Furthermore, findings show 
that it markedly elevates platelet NO synthase activity and intraplatelet levels of cGMP. 
The inhibitory action of apo-E is noticeable limited by NO synthase inhibitors (Riddell 
et al. 1997). 
 
5.3.5 Functions and cellular actions of HDL 
5.3.5.1 Task of cholesterol transport 
The most important function of HDL is reverse cholesterol transport, which represents a 
HDL mediated collection and transport of cholesterol from peripheral tissues to the liver 
for excretion, also called cholesterol efflux from peripheral tissues (Fielding and Field-
ing 1995;Sastre et al. 2002). Thus HDL have the ability to enhance the removal of 
excess cholesterol from peripheral tissues (Oram 2003). The fact that HDL represent an 
inverse risk factor for atherosclerosis (O'Connell and Genest, Jr. 2001;Okamura et al. 
2006;Sastre et al. 2002) is probably related to the ability of HDL to induce cholesterol 
efflux from vascular cells. 
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5.3.5.2 Antioxidant properties 
Another important function of HDL is the prevention of oxidative modification of LDL. 
This function is partially referred to enzymatic processes (Kontush et al. 2003;Kontush 
and Chapman 2006;Sastre et al. 2002). Morever, these antioxidant properties can be 
attributed to the apoA-I content of HDL because it contains methionine residues which 
are preferably oxidized (Garner et al. 1998). HDL can take up oxidized phospholipids 
and can then undergo oxidative modification and their protective functions can be 
manipulated. Results of studies report that HDL2 and HDL3 protect against oxidative 
modification of LDL. These modifications were detected via thiobarbituric acid reactive 
substances, lipid hydroperoxides and conjugated dienes (Huang et al. 1998;Singh et al. 
1997). Findings show that HDL2 protect LDL more effectively against oxidation by 
enzymic formation of OH- than HDL3 (Singh et al. 1997). HDL significantly inhibit the 
acceleration of oxidative modification of LDL by ascorbic acid (Sakuma et al. 2005). 
Moreover, HDL inhibit the transmigration of monocytes induced by oxidized LDL, the 
cytotoxicity induced by oxidized LDL and the oxidized LDL induced adhesion of 
monocytes to endothelial cells in vitro. ApoA-I also prevents the cytotoxicity induced 
by oxidized LDL. Exact mechanisms are currently unknown (Barter et al. 
2003a;Kontush and Chapman 2006). 
 
5.3.5.3 Influence on synthesis of nitric oxide 
HDL also play a crucial role in the synthesis and bioavailability of NO. NO synthase 
catalyses the oxidation of L-arginine to L-citrulline and NO radicals. In specific situa-
tions it is possible that eNOS becomes uncoupled and reduces molecular oxygen and it 
does not transfer electrons to L-arginine. Thus O2- radicals are generated. This can lead 
to the generation of ONOO-, which represents a potent oxidant that induces lipid and 
protein oxidation (Stocker and Keaney, Jr. 2005). Moreover, HDL containing apo-E 
elevate platelet NO synthase activity through interaction with platelet surface and there-
fore inhibit platelet aggregation (Riddell et al. 1997;Riddell and Owen 1999). HDL also 
elevate endothelial NO synthase expression. HDL enhance NO production via upregu-
lating the expression of eNOS and stimulating eNOS via activation of kinase cascade 
(Mineo et al. 2006). Another study reveals that NO synthase activity is enhanced by 
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HDL and apoA-I via protein association and multisite phosphorylation (Drew et al. 
2004). 
 
5.3.5.4 Influence on liberation of mediators 
HDL stimulate protein kinase-C, demonstrated by a transient increase in membrane as-
sociated kinase activity. It is proposed that kinase activation is dependent on binding of 
HDL3 to the HDL receptor because tetranitromethane modified HDL3, which do not 
bind to the receptor, is without effect (Mendez et al. 1991). It is also possible that HDL 
have an effect on the production of various mediators, which are inclosed in the 
development of atherosclerosis. One mediator is endothelin, a vasconstricting mitogenic 
peptide, thats secretion from endothelial cells is inhibited by HDL (Fan et al. 2000). 
Studies show that intracellular Ca2+ is increased by HDL in endothelial cells (Honda et 
al. 1999) and that the Ca2+ release from internal stores is maintained by the activation of 
phospholipase C (Mineo et al. 2006). Moreover, HDL are able to induce vasodilation in 
isolated aortae through an increase in Ca2+(Nofer et al. 2004). 
 
5.3.5.5 Antithrombotic and antiatherogenic effects 
The antiatherogenic capacity of increased HDL cholesterol concentrations in plasma is 
demonstrated also in animal models. Many of the studies on HDL attempt to assign the 
antiatherogenic action of HDL to specific particle subpopulations (Sastre et al. 2002). 
The thrombogenic risk might be reduced by counteracting or interfering with throm-
bogenic and atherogenic LDL, or by any other interaction with platelets. Likewise it is 
assumed that apo-E and apo-E containing HDL might limit lipase mediated LDL reten-
tion in the subendothelial matrix (Saxena et al. 1993). Moreover, results of a study car-
ried out with co-cultures of human aortic cells show that HDL and antioxidants can in-
hibit the transmigration of monocytes across an endothelial cell monolayer induced by 
oxidized LDL (Navab et al. 1991). Results also demonstrate that HDL and modified 
HDL partially regulate vascular tone (Martin-Nizard et al. 1995). ApoA and 
paraoxonase contents as well as the phospholipid composition define antiatherogenic 
effects of HDL. Antithrombotic properties are also defined by the abilities of HDL to 
extenuate expression of tissue factor and selectins. Purified HDL increase the inactiva-
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tion of coagulation factor Va by activated protein C and protein S in vitro that results in 
decreased thrombin generation (Griffin et al. 1999). Furthermore, HDL enhance endo-
thelial anticoagulant thrombomodulin that facilitates the generation of activated protein 
C. HDL directly and indirectly play a role in inhibiting platelet activation (Mineo et al. 
2006). Moreover, results show protective effects of HDL, because HDL are able to re-
store endothelial function in hypercholesterolemic men (Spieker et al. 2002). 
 
5.3.6 Established differences between HDL2 and HDL3 
The relative proportion of HDL3 to HDL2 in plasma is known to be dependent on differ-
ent factors, including sex, alcohol intake, exercise, smoking, obesity, and hypercholes-
terolemia (Krauss 1982). 
 
5.3.6.1 Varieties in composition 
HDL2 are composed of 60% lipids and 40% protein, whereas HDL3 are made up of 45% 
lipids and 55% protein. The ratio of phosphatidylcholin to sphingomyelin and the ratio 
of free to esterified cholesterol are higher in HDL2 than in HDL3. Approximately 90% 
of proteins in HDL consist of apoA-I and apoA-II. The composition of isolated HDL is 
dependent on the method of preparation (Assmann and Schriewer 1980). 
 
5.3.6.2 Differences in metabolism 
The metabolism of HDL2 is faster than the catabolism of HDL3. The conversion of 
HDL2 to HDL3 by means of hepatic lipase is inhibited by oestrogen and stimulated by 
androgens. Due to this, men have lower HDL2 levels than women. ApoA-I and apoA-II 
are synthesized more in women than in men (Nestel 1987). 
 
5.3.6.3 Discrepancies in race and sex 
The Bogalusa heart study demonstrates a difference in levels of HDL2 and HDL3 in 
black and white adults. Whites show significantly higher levels of VLDL, LDL and 
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lower levels of HDL2 and HDL3 than blacks. White females have significantly higher 
levels of HDL2 than white males. HDL2 and HDL3 are favorably affected by female sex 
and alcohol, whereas cigarette smoking shows unfavorable effects on VLDL and HDL3. 
The race and sex specific differences are explained by the variation in their triglyceride 
metabolic capacity. It is shown that females have a greater activity of lipoprotein lipase 
than males and males have a greater activity of hepatic lipase than females. The study 
demonstrates that blacks compared with whites have significantly higher lipoprotein 
lipase and lower hepatic lipase activities (Srinivasan et al. 2001). Another study demon-
strates that women have higher levels of HDL, HDL2, HDL3, and apoA-I and lower 
levels of ApoB than men (Gardner et al. 2000). 
 
5.3.6.4 Differences in apolipoprotein content 
Higashihara et al. and Desai et al. show that HDL2 inhibit collagen- and thrombin-
induced platelet aggregation more effectively than HDL3. The authors suggest that most 
of the inhibiting effects are situated in the HDL2 fraction due to their content of apo-E 
(Desai et al. 1989;Higashihara et al. 1991b). A study found that plasma levels of HDL 
containing both apoA-I and apoA-II (apoA-I/apoA-II) are 2.5 times higher than levels 
of apoA-I without apoA-II (apoA-I). The proportion of apoA-I associated with HDL2 is 
greater than that of apoA-I/apoA-II. Furthermore, an increase in levels of HDL2 causes 
an enhancement of the proportion of apoA-I in HDL2. ApoA-I/apoA-II show a positive 
association with plasma LCAT activity within HDL3, but not within HDL2. Besides, 
apoA-I demonstrates an inverse association with plasma CETP mass, which was quanti-
fied using an immunoradiometric assay with polyclonal anti-CEPT antibody (Mowri et 
al. 1994). 
 
5.3.7 HDL and various determinants 
5.3.7.1 Impact of alcohol 
A highly significant increase of lipids and apolipoproteins in HDL and its subfractions 
in alcohol consumers was measured. The increase in HDL2 is more than twice of the 
increase in the HDL3 subclass, which shows a higher HDL lipid load in alcohol con-
 26 
sumers (Schafer et al. 2007). Another study demonstrates an increase in total HDL cho-
lesterol and apoA-I due to alcohol. This finding is referred to HDL3 cholesterol, because 
the association seems to be linear. The study reveals that HDL2 are increased just after 
high alcohol consumption levels and that they are diminished significantly among mod-
erate drinking women (10–20 g/day) (Sillanaukee et al. 2000). 
 
5.3.7.2 Effect of sports 
Within a study on effects of sports changes in lipid profiles were measured and among 
other things blood samples were collected 24h post exercise and compared to samples 
collected pre exercise. It is shown a significant increase in 24h post exercise HDL at 
lactate threshold intensity, possibly due to increases in both HDL2 and HDL3 subfrac-
tions. Although 24h free cholesterol is increased significantly as well. The increase in 
HDL involves decreases in TG and VLDL at 24h post exercise. Hence the lactate 
threshold intensity might appear to be the threshold intensity of acute aerobic exercise 
necessary to promote a significant increase in HDL (Park and Ransone 2003). Studies 
reveal that exercise is associated with a significant increase in apoA-I and apoA-I/apoA-
II and unchanged apoA-II. These findings support the assumption that exercise in-
creases HDL2 fraction (Kullmer and Kindermann 1985). Aerobic physical exercise is 
the exercise of choice to increase HDL (Watts and Burnett 2004). 
 
5.3.7.3 Implications of selected diseases 
5.3.7.3.1 Breast cancer 
Michalaki et al. show that breast cancer patients have a higher risk for developing other 
chronic diseases including cardiovascular disease. In patients with breast cancer com-
pared to the controls an increase in TG and a decrease in HDL, especially in the HDL2 
subfraction, is shown. Untreated breast cancer patients have unfavourable lipid profiles 
with high atherosclerosis indexes (Michalaki et al. 2005). 
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5.3.7.3.2 Non insulin dependent diabetics 
There seems to exist a statistically significant decrease in HDL, HDL2 and HDL3 in 
comparison to non diabetic controls. A higher decrease of cholesterol is shown in HDL2 
than in HDL3 subclass in the comparisons between non insulin dependent diabetes mel-
litus (NIDDM) with CAD and CAD subjects without NIDDM (Bakogianni et al. 2001). 
 
5.3.7.3.3 Myocardial infarction 
ApoA-I and apoA-II concentrations are both significantly lower in patients with myo-
cardial infarction (MI). These differences remain even after adjustment for coronary risk 
factors and lipids. Apo-B and apo-E concentrations are not significantly related to MI 
after these adjustments. Both HDL2 and HDL3 cholesterol levels are significantly asso-
ciated with MI. Especially apoA-I and apoA-II may give considerable information to 
determination of risk of MI (Buring et al. 1992). 
 
5.3.7.4 Rising HDL by means of medication  
5.3.7.4.1 Fibrates 
TG are reduced by fibrates up to 50%, whereas HDL are enhanced by 5-25% due to the 
increase in the concentration of apoA-I and apoA-II. Fibrates activate peroxisome pro-
liferator activated receptor alpha (PPARα). PPARα activators increase the synthesis of 
apoA-I, apoA-II, lipoprotein lipase, ATP binding cassette A1 (ABCA1) and scavenger 
receptor type B1 (SR-B1). The selective hepatic uptake of CEs is enhanced due to the 
increase in SR-B1. Increases in ABCA1 and SR-B1 both have the capacity to increase 
reverse cholesterol transport. Fibrates may thereby enhance the antiatherogenic function 
of HDL and they have a direct antiinflammatory effect by virtue of their ability to acti-
vate PPARα in the artery wall (Barter et al. 2003a). 
 
5.3.7.4.2 Statins 
The increase in the concentration of HDL by statins is generally in the range of 5-10%. 
This increase is achieved at relatively low doses of statins. In some cases the effect is 
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already maximal at the lowest recommended dose. Statins activate PPARα as do fi-
brates, but the mechanism of activation is different and the inhibition of the Rho family 
of small GTP proteins is involved. Rho activity is upregulating the activity of PPARα. 
There exists a synergistic activation of PPAR by simultaneous treatment with statins 
and fibrates. Statins also have the ability to inhibit CETP (Barter et al. 2003a). 
 
5.3.7.4.3 Niacin 
The synthesis of both apoA-I and apoA-II is stimulated by niacin. HDL are thus com-
monly increased by 30%. There exist unpleasant side effects, but when added at very 
low doses to statin therapy, niacin significantly increases the concentration of HDL, 
though the mechanism by which niacin increases the concentration of HDL is not 
known (Barter et al. 2003a). 
 
5.3.7.4.4 Inhibitors of CETP 
A deficiency of CETP is associated with increased HDL levels, decreased LDL levels 
and decreased apo-B levels. Small molecule inhibitors of CETP are able to provoke this 
profile in human subjects (Barter et al. 2003b). 
 
5.3.8 Oxidative modification of HDL  
Lipid and protein oxidation in the vascular wall is accepted to contribute to atheroscle-
rosis. It is not known if oxidative stress in general or the oxidative modification of LDL 
in particular is jointly responsible for pathogenesis of atherosclerosis. The fact that LDL 
are linked to atherosclerosis is well established because reducing high cholesterol repre-
sents a very effective therapy (Stocker and Keaney, Jr. 2005). Sources for oxidative 
stress are hypercholesterolemia, diabetes, hypertension, cigarette smoking, aging, and 
nitrate tolerance. These risk factors increase the production of reactive oxygen species 
(ROS). ROS lead to altered vasomotion, matrix metalloproteinase activation, lipoprotein 
oxidation, apoptosis, vascular smooth muscle cell growth, and adhesion molecule ex-
pression via various enzyme systems, xanthine oxidase, mitochondrial sources, and 
NOS, respectively (Harrison et al. 2003). The oxidative modification hypothesis sup-
poses that oxidation of proteins and lipids, mostly modification of LDL, lead to devel-
 29 
opment of atherosclerosis and that these changes can be prevented by antioxidants 
(Jessup et al. 2004). It is not known how and where LDL get oxidized and if results ob-
tained by trials in vitro are also of importance in vivo (Chisolm and Steinberg 2000). 
Several studies with β-carotene and vitamin E were conducted, but no beneficial effects 
of these antioxidants on cardiovascular events are shown (Knekt et al. 2004;Steinberg 
and Witztum 2002;Vivekananthan et al. 2003). 
 
5.3.8.1 The importance of myeloperoxidase derived hypochlorite 
The MPO - H2O2 – Cl- system forms hypochlorite (OCl-) in activated neutrophils and 
monocytes in vivo and may react with lipids, antioxidants and proteins. OCl- represents 
a most important proinflammatory chlorinating oxidant generated by MPO (Malle et al. 
2006b;Marsche et al. 2008). The presence of enzymatically active MPO in human 
atherosclerotic lesions, the presence of hypochlorous acid (HOCl) modified lipoproteins 
and proteins in advanced human atherosclerotic lesions and inflammatory kidney tissues 
demonstrate the importance of MPO as a potent in vivo oxidant. MPO catalyzes oxida-
tive reactions in the vascular wall and thereby may play a part in the development of 
atherosclerosis (Daugherty et al. 1994). Another finding, why MPO presumably is asso-
ciated with atherosclerosis, is that atheroprotective activities of HDL are decreased and 
linked to lesions in HDL, which are modified by MPO and HOCl (Nicholls et al. 2005). 
Furthermore, MPO catalyzed oxidation products are highly enriched in circulating HDL 
from individuals with cardiovascular diseases where MPO concentrations are also in-
creased and thus elevated MPO levels are linked to occurrence of CAD (Malle et al. 
2006b;Zhang et al. 2001). Oxidation of HDL is shown to result in decreased cholesterol 
efflux in macrophages and findings referred to changes of the apolipoprotein domain 
(Bergt et al. 1999). Moreover, studies show that these changes result in modifications in 
the protein moiety apoA-I and in the conversion of HDL into a proatherogenic lipopro-
tein particle. Furthermore, also biophysical trials show that MPO binding is possible 
through this specific interactions with apoA-I. Specific targets for nitration and chlori-
nation of specific tyrosine residues catalyzed by MPO are identified on apoA-I (Zheng 
et al. 2005). The ability of HDL to promote cellular cholesterol efflux via the ABCA1 
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transport system is detracted after the MPO catalyzed oxidation of apoA-I (Nicholls et 
al. 2005). 
 
5.3.8.2 Relevance of 2-Chlorohexadecanal 
2-ClHDA is derived from HOCl mediated oxidative cleavage of HDL associated 
plasmalogen. 2-ClHDA represents the main α-chloro fatty aldehyd build from cell 
associated plasmalogen (Thukkani et al. 2002). Plasmalogens are situated in the plasma 
membranes of mammalian cells and in lipoproteins and are thought to be antioxidants 
because the vinyl ether bond is susceptible to attack by oxidants. Findings demonstrate 
that the vinyl ether bonds of plasmalogens are highly amenable to reactive chlorinating 
species generated by the MPO hydrogen peroxide chloride system. 
Lysophosphatidylcholine and α-chlorinated fatty aldehyds are generated (Albert et al. 
2001). Furthermore, results of studies suggest that 2-ClHDA is able to modulate eNOS 
expression and activity. A time dependent and concentration dependent decrease of NO 
production in human umbilical venous endothelial cells was measured (Marsche et al. 
2004). Moreover, studies show that 2-ClHDA is produced as a result of a neutrophil 
dependent MPO based mechanism, which constitutes an answer to regional myocardial 
infarction and it might also contribute to cardiac dysfunction (Thukkani et al. 2005). 
Neutrophil recruitment is shown to be induced by physiologically relevant concentra-
tions of 2-ClHDA in vitro. Because of this, the authors assume that α-chloro fatty alde-
hydes take part in neutrophil recruitment of neutrophil mediated inflammation in vivo 
(Thukkani et al. 2002). 
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6 Materials and laboratory equipment 
6.1 Material 
6.1.1 Chemicals 
Sodium hypochlorite (Sigma-Aldrich) 
Methionine (Sigma-Aldrich) 
ADP (Sigma-Aldrich) 
Collagen reagens Horm (Nycomed) 
Thrombin (Sigma-Aldrich) 
PGE1 (Sigma-Aldrich) 
Sepharose 4B (GE Healthcare) 
Antibodies: 
Polyclonal anti-mouse IgG antibody (cat. 349031, FITC conjugated, Becton Dick-
inson) 
Monoclonal anti CD62 (cat. 348107, PE conjugated, Becton Dickinson) 
Monoclonal anti-phospho-VASP (cat. 0153S0202, pSer 239, clone 22E11, 
nanoTools) 
 
6.1.2 Buffers and Solutions 
10% formaldehyde solution (Sigma Aldrich) in 0.9% sodium chloride solution 
0.2% triton solution (Triton x-100, Sigma Aldrich) in PBS 
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Tyrode-HEPES buffer (with glucose and albumin) 
140mM sodium chloride 
3mM potassium chloride 
1mM magnesium hydrogen carbonate 
10mM HEPES 
(5.5mM D-glucose) 
(0.5% human serum albumin) 
pH: 7.4 
 
Borate buffer with EDTA 
0.1M borate 
100µM EDTA 
pH: 7.2 
 
Borate buffer with sodium chloride 
0.1M borate 
0.05M sodium chloride 
pH: 7.2 
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Dulbecco´s phosphate buffered saline (PBS) 
1.5mM potassium phosphate monobasic 
2.7mM potassium chloride  
137mM sodium chloride 
8.3mM sodium phosphate dibasic (anhydrous) 
pH: 6.8 
 
Solutions for Lowry procedure 
A1: 1g CuSO4*5H2O in 100ml water distilled 
A2: 2g K-Na-tartrat in 100ml water distilled 
B:   50ml 2% (w/v) sodium carbonate + 1ml A 
       (A: 500µl A1 + 500µl A2) 
C:   Folin reagent + water distilled (1:1) 
D:  1 N sodium hydroxide 
 
6.2 Laboratory equipment 
• Ultracentrifuge - Optima LXP Series with a 50.2 Ti rotor (Beckman Coulter) 
• Centrifuge - Allegra X12R (Beckman Coulter) 
• Analytic Flow Cytometer - FACSCalibur dual-laser (Argon-488nm and 635nm di-
ode) (Becton Dickinson) 
• Spectrophotometer - U-3010 (Hitachi) 
• Microplate Reader - Anthos HT III (Anthos) 
• Spectra Max Gemini XS (Molecular Devices) 
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7 Methods 
7.1 Lipoprotein preparation 
Blood of 24 healthy donors was centrifuged at 2000g for 20min. Blood plasma was 
separated as supernatant from the remaining blood and immediately frozen. Blood 
plasma was centrifuged in the presence of salt having a density suitable for separating 
the lipoproteins. 
First VLDL were isolated. A density of 1.019g/ml was required, this equated to a 2.85% 
potassium bromide solution. The density of the blood plasma had to be adjusted, it was 
already one of a 1.1% potassium bromide solution, so the difference value amounted to 
1.75%. Addition of potassium bromide: g (salt) = g (plasma) * 1.75 / 98.25 
Each centrifuge tube was filled up with 15ml plasma and was overlaid by a potassium 
bromide solution of identical density (2.85%). The centrifuge tubes were centrifuged at 
100 000g at 4 C° for 16 hours. Then VLDL could be removed as supernatant from the 
remaining plasma with a syringe. The centrifuge tubes were always kept on ice. 
Then LDL were isolated. KBr was added to the remaining plasma until it reached a 
density of 1.063g/ml, this equated to a 8.6% potassium bromide solution. Addition of 
potassium bromide: g (salt) = g (plasma) * 5.75 / 94.25 
Each centrifuge tube was filled up with 15ml plasma and was overlaid by a potassium 
bromide solution of identical density (8.6%). The centrifugation at this point took 20 
hours at 100 000g and at 4C°. LDL could be separated as aforementioned for VLDL, 
and were filtered with Rotilabo syringe filter (0.45µm, PVDF, Roth). 
Afterwards HDL2 were isolated. KBr was added to the remaining plasma until a density 
of 1.125g/ml, which equated to a 16.1% potassium bromide solution. Addition of 
potassium bromide: g (salt) = g (plasma) * 7.5 / 92.5 
Each centrifuge tube was filled up with 15ml plasma and was overlaid by a potassium 
bromide solution of identical density (16.1%). Accordingly the plasma was centrifuged 
for 36 hours at 100 000g and at 4C°. HDL2 could be separated as aforementioned and 
were filtered with Rotilabo syringe filter (0.45µm, PVDF, Roth). 
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Thereafter HDL3 were isolated. KBr was added to the remaining plasma until a density 
of 1.21g/ml, which equated to a 25.2% potassium bromide solution. Addition of 
potassium bromide: g (salt) = g (plasma) * 9.1 / 90.9 
Each centrifuge tube was filled up with 15ml plasma and was overlaid by a potassium 
bromide solution of identical density (25.2%). The plasma was centrifuged for 40 hours 
at 100 000g and at 4C°. HDL3 could be separated as aforementioned and had to be 
filtered with Rotilabo syringe filter (0.45µm, PVDF, Roth) as well. Lipoproteins were 
stored at 4C°.  
Lipoprotein fractions used were HDL2 and HDL3. 
 
7.2 Native HDL 
Native HDL (nHDL) obtained by ultrazentrifugation contained potassium bromide, 
which was eliminated by rebuffering in Econo-Pac 10DG columns equilibrated with 
borate buffer containing 0.9% sodium chloride. 
 
7.3 Modification of HDL 
First nHDL were rebuffered in Econo-Pac 10DG columns equilibrated with borate 
buffer and EDTA to avoid oxidative modification of HDL by iron. Then lipoproteins 
were modified with hypochlorite. Different degrees of oxidatively modified HDL were 
obtained by using different molar excess of hypochlorite: 
Maximal oxidation: hypochlorite was added until HDL were completely bleached. Hy-
pochlorite was added in steps of 1µl and promptly mixed on vortex. 
Medium oxidation: half of the volume of hypochlorite needed for maximal oxidation 
was added. 
Minimum oxidation: fourth of the volume needed for maximal oxidation was added. 
Reduction: maximally oxidized HDL were incubated with methionine [final concentra-
tion (f.c.): 12mM] for 10 minutes. 
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Afterwards each state of modification had to be rebuffered in Econo-Pac 10DG columns 
equilibrated with borate buffer containing 0.9% sodium chloride.  
 
7.4 Protein determination - Lowry procedure 
Protein content of lipoproteins was quantified according to Lowry. The Lowry method 
is sensitive to low concentrations of protein. Under alkaline conditions the divalent cop-
per ion forms a complex with peptide bonds in which it is reduced to a monovalent ion. 
Monovalent copper ion and the radical groups of tyrosine, tryptophan, and cysteine re-
act with Folin reagent to produce an unstable product that becomes reduced to molyb-
denum/tungsten blue.  
Procedure for proteins in solution: 
Different dilutions of proteins were prepared. 250µl of the protein containing solutions 
were added to 125µl of solution D. The test tubes were incubated for 30 minutes at 
room temperature. Then 1.25ml of solution B were added. After an incubation of 10 
minutes 125µl of solution C were added. Each tube was mixed immediately and incu-
bated for another 30 minutes. The absorbance of each sample was determined at 750nm. 
Data were analysed with a calibration curve constructed by known concentrations of 
bovine serum albumin. 
 
7.5 Platelet isolation 
Blood was obtained from healthy humans, either subjects from the centre of Physiology 
and Pathophysiology or platelet donors from the Vienna general hospital, who were free 
of medication for the last 2 weeks. Fresh human blood was drawn into acid citrate dex-
trose (3.8%). Platelet rich plasma (PRP) was obtained by centrifugation at 125g for 
20min. The obtained PRP was gel filtrated. Gel filtration was performed on a Sepharose 
4B column, which was equilibrated with HEPES-Tyrode buffer containing 0.5% human 
serum albumin. This was essential to get non activated platelets and to obtain platelet 
counts comparable to that observed in PRP. Gel-filtrated platelets (GFP) were eluted 
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with HEPES-Tyrode buffer. Subsequently platelets were kept at room temperature and 
used immediately for experiments.  
 
7.6 FACS analysis 
7.6.1 Quantification of vasodilator stimulated phosphoprotein 
VASP-P was induced by PGE1 and was used as indicator for inhibition of platelets 
(5.2.3.1). 
300µl of GFP were incubated with HDL2 and HDL3 (7.2, 7.3) in Eppendorf tubes for 10 
minutes at room temperature. Final concentrations of HDL added mounted up to 
100µg/ml. Trials were also carried out with 2-ClHDA (f.c.: 2µM and 1µM), which was 
incubated with platelets in Eppendorf tubes for 10 minutes at room temperature.  
All tests were performed in Cellstar TC-plates (96well, V-shape, Greiner Bio-One). Pro-
cedure is the same for HDL2 and HDL3 as well as for 2-ClHDA. PGE1 (f.c.: 6.7nM, 
16.7nM, 33.3nM) was added to 30µl of platelets and incubated for exact 2 minutes at 
room temperature. PGE1 (f.c.: 33.3µM) was used as control for maximal possible 
VASP-P. Subsequently incubation with ADP (f.c.: 83.3µM), which was used as control 
because phosphorylation should be low after ADP activation in platelets, for a duration 
of 5 minutes started. Fixing of platelets was arranged at a final concentration of 1.6% 
formaldehyde solution for 15 minutes. Membranes of platelets were permeabilized by 
triton solution (f.c.: 0.02%). After centrifugation at 1700g for 10 minutes pellets were 
suspended in 70µl of PBS. There were two steps of labelling of platelets. First 5µl of 
pre-dilution of anti-phospho-VASP (Ser 239) (43µg/ml) were added to each sample and 
incubated for 45 minutes. Then there was another centrifugation for eliminating un-
bound antibody and subsequently platelets were re-suspended in 35µl of PBS. FITC 
labelled GAM antibody was added and incubated with platelets for 15 to 30 minutes in 
the dark. There were used 4µl of antibody solution per sample. Samples were trans-
ferred into FACS test tubes and diluted with 300µl of PBS. Finally measurement by 
flow cytometry was performed. Emitted light was collected in the fluorescence 1 (FL1) 
channel.  
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7.6.2 Quantification of P-selectin positive cells 
P-selectin, stored in α-granules, is expressed on the surface of platelets after activation. 
Percentage of CD62 antibody positive platelets was determined.  
First 300µl of GFP were incubated with HDL2 and HDL3 (see methods 6.2 native HDL 
and 6.3. modification of HDL) in Eppendorf tubes for 10 minutes at room temperature 
similar to quantification of VASP. Final concentrations were 100µg/ml for nHDL and 
150µg/ml for hypochlorite modified HDL (hyp-OxHDL). Additionally two different 
trials with 2-ClHDA were carried out. For the first trial, 300µl of platelets were incu-
bated with 2-ClHDA (f.c.: 0µM, 0.05µM, 0.1µM, 0.5µM, 1µM) in Eppendorf tubes for 
10 minutes at room temperature. For the second one, 2-ClHDA (f.c.: 1.27nM, 7.6nM) 
was shortly incubated with nHDL2 and nHDL3 (f.c.: both 100µg/ml) in Eppendorf tubes 
and afterwards platelets were added and incubated for another 10 minutes at room tem-
perature. 
All tests were performed in Cellstar TC-plates (96well, V-shape, Greiner Bio-One). Pro-
cedure is equal for HDL2 and HDL3 as well as for 2-ClHDA. Subsequent incubation 
with different platelet agonists, such as ADP, collagen, or thrombin at different concen-
trations with 30µl of platelets started for 5 minutes at room temperature. 
Different final concentrations: 
 ADP 1.7µM 4.2µM 8.3µM 
 Collagen 40µg/ml 50µg/ml 100µg/ml 
 Thrombin 6.7U/ml 16.7U/ml 33.3U/ml 
Table 1: Final concentrations of platelet agonists 
Fixing of platelets was arranged at a final concentration of 1.6% formaldehyde solution 
for 15 minutes. Then centrifugation at 1700g for 10 minutes was performed and pellets 
were suspended in 30µl of PBS. 2µl of CD62 antibody were added to each test and an 
incubation of one hour was performed. Samples were transferred into FACS test tubes 
and diluted with 300µl of PBS. The fluorescence was measured in FL2.  
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7.7 Determination of platelet aggregation using microplate 
reader 
The principle of determination of platelet aggregation is based upon changes in light 
transmission. This light transmission increases with aggregation and was measured at a 
wavelength of 405nm. Light is sent through a microtiter well and the beam of light 
modified by platelet aggregation in the microplate well is measured by a detector.  
Cellstar tissue culture plates (96well, flat bottom, Greiner Bio-One) were used. 2-
ClHDA (f.c.: 1µM and 2µM) and ADP (f.c.: 50µM) as control were added to 50µl of 
GFP and aggregation was immediately measured at 37C°. There were forty cycles per 
twenty seconds (shaking for ten seconds, optical measurement). 
 
7.8 Quantification of free amino groups 
Changes in the number of free amino groups were quantified for further characterisation 
of nHDL and hyp-OxHDL. Determination was carried out with fluorescamin that reacts 
with free amino groups to a fluorescent product. For this determination fluorescamin 
was dissolved in acetone (540µM in acetone). HDL were diluted to a concentration of 
500µg/ml, thereafter borate buffer was added at a ratio of 1: 7.5 (HDL : borate buffer). 
Afterwards fluorescamin was added and amounted to fourth of the final volume. After 
this, readings at 390/475nm were performed. 
 
7.9 Quantification of chloramines 
Since N-Cl derivatives oxidize the sulfhydryl group of TNB2- to disulphide (DTNB), 
this method facilitates photometrical detection of chloramines. Concentrations of TNB2- 
were determined in a photometer at a wavelength of 412nm and these concentrations 
were calculated via the molar extinction coefficient. 
100mM DTNB [5.5'-Dithio-bis(2-nitrobenzoic acid)] were hydrolysed in 0.1M NaOH 
for 5 minutes leading to TNB2- formation. After centrifugation TNB2- (in the super-
natant) was diluted with PBS at a ratio of 1:50. At this point first measurement was car-
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ried out. The second measurement was conducted after addition of the sample (blank 
value against buffer). There was a surplus of TNB2- admixed and the difference between 
primarily added TNB2- and the portion remaining after oxidation with N-Cl was calcu-
lated. Hence it was possible to quantify the number of chloramines. 
Formula for calculating chloramines per HDL: 
 
(TNB2- primarily - TNB2- after oxidation with N-Cl) 
                    2 *13600 * mol HDL added 
 
7.10 2-Chlorohexadecanal 
Synthesis was carried out at our laboratory and was based on Van den Bergen (Van den 
Bergen et al. 1999). 2-ClHDA was synthesized in two steps by chlorination of n-
hexadecanal dimethylacetal. 
2-ClHDA was dissolved in dimethyl sulfoxide (DMSO). 23mg were diluted in 1ml 
DMSO. Pre-dilutions of 2-ClHDA were made and amounted to 0.1µg/µl. Different final 
concentrations (0µM, 0.5µM, 1µM, 2µM, 5µM, 10µM, 20µM) were prepared and final 
concentrations of DMSO had to be below 0.5%, because DMSO itself possibly leads to 
aggregation defects in platelets (Cetin et al. 2001). DMSO and PBS were used as con-
trol. 
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8 Results 
8.1 Experiments with native HDL2 and HDL3 
8.1.1 Effects of nHDL2 and nHDL3 on VASP-P 
Phosphorylation state of VASP closely correlates with the inhibition of platelets and is 
therefore used as indicator for inhibitability of platelets (5.2.3.1) within the following 
experiments. Impact of nHDL2 and nHDL3 on PGE1-induced VASP-P in GFP was de-
termined by FACS analysis.  
The first set of experiments was performed to clarify how nHDL2 affect VASP-P and 
whether these effects are dose-dependent, or not. GFP were treated with specified con-
centrations of nHDL2 (50µg/ml, 100µg/ml, 150µg/ml) and VASP-P was induced by 
different PGE1 concentrations (6.7nM, 16.7nM, 33.3nM).  
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Figure 1: Effects of nHDL2 (50µg/ml, 100µg/ml, 150µg/ml) on PGE1-induced VASP-P in GFP 
(HDL from 4 donors, n=12). 
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Table 2: According to Figure 1 - mean values and standard deviations of results of PGE1-
induced VASP-P in GFP incubated with nHDL2 (50µg/ml, 100µg/ml, 150µg/ml).  
 
Figure 1 shows PGE1-induced VASP-P in GFP without nHDL as 100%, which hence 
constitutes the control. Changes of VASP-P in GFP incubated with nHDL2 are expressed 
in percent relative to control. Incubation of GFP with increasing concentrations of 
nHDL2 leads to increasing VASP-P, which indicates their platelet-inhibiting properties. 
Dose-dependent effects of nHDL2 on PGE1-induced VASP-P are shown. Unfortunately 
standard deviations are quite high.  
 
As for nHDL2, effects of nHDL3 on PGE1-induced VASP-P were evaluated by quantify-
ing VASP-P positive cells. GFP were treated with nHDL3 at three different concentra-
tions (50µg/ml, 100µg/ml, 150µg/ml) and VASP-P was induced by different concentra-
tions of PGE1 (6.7nM, 16.7nM, 33.3nM).  
 
 nHDL2 (50µg/ml) nHDL2 (100µg/ml) nHDL2 (150µg/ml) 
 Mean ± SD Mean ± SD Mean ± SD 
  6.7nM PGE1 112.3 ± 26.4 137.2 ± 29.8 157.3 ± 55.8 
16.7nM PGE1 138.0 ± 94.8 150.3 ± 66.3 148.0 ± 109.6 
33.3nM PGE1 125.6 ± 28.5 157.8 ± 78.6 205.9 ± 190.7 
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Figure 2: Effects of nHDL3 (50µg/ml, 100µg/ml, 150µg/ml) on PGE1-induced VASP-P in GFP 
(HDL from 4 donors, n=12). 
 
 nHDL3 (50µg/ml) nHDL3 (100µg/ml) nHDL3 (150µg/ml) 
 Mean ± SD Mean ± SD Mean ± SD 
  6.7nM PGE1 163.1 ± 94.0 145.3 ± 99.4 142.0 ± 77.8 
16.7nM PGE1 108.9 ± 71.0 123.7 ± 58.4 232.9 ± 70.5 
33.3nM PGE1 73.3 ± 12.9 212.3 ± 162.8 136.4 ± 42.6 
Table 3: According to Figure 2 - mean values and standard deviations of results of PGE1-
induced VASP-P in GFP incubated with nHDL3 (50µg/ml, 100µg/ml, 150µg/ml). 
 
As shown in Figure 2, PGE1-induced VASP-P in GFP without nHDL3 is used as control 
and set 100%. VASP-P in GFP incubated with nHDL3 is expressed in percent relative to 
control. nHDL3 have the potential to increase VASP-P in GFP despite at a concentration 
of 50µg/ml at 33.3nM PGE1, which is probably a maverick. This indicates platelet-
inhibiting effects of nHDL3. Moreover, a concentration dependency of nHDL3 on 
16.7nM PGE1-induced VASP-P is shown. Due to high standard deviations a clear con-
clusion can not be made. 
 
 44 
8.1.1.1 Calculation of effects of nHDL2 and nHDL3 (50µg/ml) on VASP-P 
Obtained values from experiments, which indicated effects of nHDL2 and nHDL3 on 
PGE1-induced VASP-P (Figure 1, Figure 2) were used as basis for calculation of influ-
ences of nHDL subclasses at a concentration of 50µg/ml on VASP-P induced by differ-
ent concentrations of PGE1. With these data a comparison between nHDL2 and nHDL3 
is possible. 
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Figure 3: Effects of nHDL2 and nHDL3 (50µg/ml) on PGE1-induced VASP-P in GFP (HDL from 
4 donors, n=12). 
 
  control nHDL2 (50µg/ml) nHDL3 (50µg/ml) 
  Mean ± SD Mean ± SD Mean ± SD 
  6.7nM PGE1 4.6 ± 3.1 5.3 ± 4.2 7.2 ± 4.1 
16.7nM PGE1 11.4 ± 8.9 14.5 ± 11.6 11.8 ± 6.5 
33.3nM PGE1 19.8 ± 14.3 22.9 ± 15.7 27.9 ± 5.9 
Table 4: According to Figure 3 - mean values and standard deviations of results of PGE1-
induced VASP-P in GFP incubated with nHDL2 and nHDL3 (50µg/ml). 
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Figure 3 shows percentages of VASP-P positive cells. Both nHDL subclasses are associ-
ated with enhanced percentages of VASP-P positive cells compared to control. nHDL3 
increase VASP-P induced by 6.7nM and 33.3nM PGE1 more effectively than nHDL2, 
but at 16.7nM PGE1 results are contrary. Differences between nHDL2 and nHDL3 are 
increasing with rising PGE1 concentrations. Unfortunately results show no significance 
because of high standard deviations. 
 
8.1.1.2 Effects of nHDL2 and nHDL3 (100µg/ml) on VASP-P 
The following experiments were designed to show the effects of nHDL2 and nHDL3 at a 
concentration of 100µg/ml on PGE1-induced VASP-P. GFP were treated with nHDL2 
and nHDL3 (100µg/ml) and VASP-P was induced by different PGE1 concentrations 
(6.7nM, 16.7nM, 33.3nM). 
Figure 4 demonstrates a dot plot obtained by detecting VASP-P positive cells in PGE1-
stimulated GFP by means of flow cytometry.  
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Figure 4: A typical result of an experiment. PGE1-induced VASP-P in GFP incubated with 
nHDL2 and nHDL3 (100µg/ml). 
A: basal 
B: PGE1 (33.3µM) 
C: PGE1 (33.3nM) 
D: PGE1 (33.3nM) + nHDL2 (100µg/ml) 
E: PGE1 (33.3nM) + nHDL3 (100µg/ml) 
Percentages in the upper right indicate percentage of VASP-P positive cells. 
 
As shown in Figure 4, nHDL2 and nHDL3 (D, E) show an enhancement in phosphoryla-
tion compared to GFP without nHDL (C). VASP-P of GFP without nHDL induced by a 
high concentration of PGE1 is also shown (B). Furthermore, the result of this experi-
ment demonstrates that nHDL3 (E) are associated with a slightly higher impact on in-
creasing VASP-P than nHDL2 (D).  
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In Figure 5, results of 24 experiments are outlined to show significant data.  
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Figure 5: Effects of nHDL2 and nHDL3 (100µg/ml) on PGE1-induced VASP-P in GFP (HDL from 
11 donors, n=24). 
 
  control nHDL2 (100µg/ml) nHDL3 (100µg/ml) 
  Mean ± SD Mean ± SD Mean ± SD 
  6.7nM PGE1 5.2 ± 4.5 6.0 ± 3.8 8.3 ± 5.6 
16.7nM PGE1 10.8 ± 9.4 14.8 ± 8.9 19.6 ± 16.7 
33.3nM PGE1 14.6 ± 12.5 21.5 ± 15.0 18.0 ± 13.0 
Table 5: According to Figure 5 - mean values and standard deviations of results of PGE1-
induced VASP-P in GFP incubated with nHDL2 and nHDL3 (100µg/ml). 
 
Figure 5 indicates VASP-P positive cells in percent. Both nHDL subclasses are able to 
increase PGE1-induced VASP-P in GFP. nHDL3 tend to show a higher percentage in 
VASP-P positive cells than nHDL2 at concentrations of 6.7nM and 16.7nM PGE1-
induced VASP-P, but at 33.3nM PGE1 results are inverse. Effects are not continuous 
throughout all concentrations of PGE1. Because of high standard deviations, it is not 
possible to draw a clear conclusion. 
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8.1.1.3 Calculation of effects of nHDL2 and nHDL3 (150µg/ml) on VASP-P 
Data of results of experiments dealing with the influence of nHDL2 and nHDL3 on 
PGE1-induced VASP-P (Figure 1, Figure 2) were used as basis for calculation of effects 
of nHDL subclasses (150µg/ml) on VASP-P induced by different concentrations of 
PGE1 to study differences between these nHDL subclasses. 
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Figure 6: Effects of nHDL2 and nHDL3 (150µg/ml) on VASP-P in GFP induced by PGE1 (HDL 
from 4 donors, n=12). 
 
  control nHDL2 (150µg/ml) nHDL3 (150µg/ml) 
  Mean ± SD Mean ± SD Mean ± SD 
  6.7nM PGE1 4.6 ±  3.1 6.6 ±  4.1 6.4 ± 2.8 
16.7nM PGE1 11.4 ±  8.9 13.0 ±  9.2 26.2 ± 11.1 
33.3nM PGE1 19.8 ± 14.3 25.1 ± 12.4 51.6 ± 15.8 
Table 6: According to Figure 6 - mean values and standard deviations of results of PGE1-
induced VASP-P in GFP incubated with nHDL2 and nHDL3 (150µg/ml). 
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Figure 6 demonstrates percentages of VASP-P positive cells. Both nHDL subclasses 
exhibit higher percentages of VASP-P positive cells than the control, but effects of 
nHDL3 on PGE1-induced VASP-P are more distinctive than effects of nHDL2. Further-
more, the amount of these effects increases with enhanced concentrations of PGE1 and 
also the differences between the nHDL subclasses get more intense with rising concen-
trations of PGE1. Incubation of GFP with nHDL3 leads to more potent effects on in-
creasing PGE1-induced VASP-P than nHDL2 at least at 16.7 and 33.3nM PGE1. 
 
8.1.2 Influence of nHDL2 and nHDL3 on ADP-induced P-selectin sur-
face expression 
P-selectin is used as indicator for platelet degranulation and secretion. It is expressed on 
the surface of platelets after their activation, which can be induced by different agonists 
like ADP, thrombin, or collagen.  
The following experiments were planned to investigate the influence of nHDL2 and 
nHDL3 on ADP-induced P-selectin expression. GFP were incubated with nHDL2 and 
nHDL3 (100µg/ml) and platelets were stimulated by different concentrations of ADP 
(1.7µM, 4.2µM, 8.3µM). 
 
 50 
0
20
40
60
80
100
1.7µM 4.2µM 8.3µM
ADP
%
 
P-
se
le
ct
in
 
po
si
tiv
e 
ce
lls
control
nHDL-2 (100µg/ml)
nHDL-3 (100µg/ml)
 
Figure 7: Influence of nHDL2 and nHDL3 (100µg/ml) on ADP-induced expression of P-selectin in 
GFP (HDL from 17 donors, n=23). 
 
 nHDL2 (100µg/ml) nHDL3 (100µg/ml) 
 Mean ± SD Mean ± SD 
1.7µM ADP 87.0 ± 5.0 85.9 ± 10.7 
4.2µM ADP 89.4 ± 12.5 95.2 ± 2.6 
8.3µM ADP 82.6 ± 14.3 79.0 ± 13.3 
Table 7: According to Figure 7 - mean values and standard deviations of results of ADP-induced 
expression of P-selectin in GFP incubated with nHDL2 and nHDL3 (100µg/ml). 
 
Figure 7 shows ADP-induced P-selectin expression in GFP without any nHDL as 100%. 
The amount of P-selectin expression in GFP with different HDL subclasses is shown in 
relation to control. nHDL2 and nHDL3 impair ADP-induced P-selectin expression in 
GFP, but there seems to be no definite finding whether nHDL2 or nHDL3 have more 
inhibiting effects on ADP-induced platelet degranulation of P-selectin in GFP. Results 
do not differ much and additionally standard deviations are quite high. 
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8.1.3 Influence of nHDL2 and nHDL3 on thrombin-induced P-selectin 
surface expression 
The aim of these experiments was to gather information about the effects of nHDL2 and 
nHDL3 on thrombin-induced P-selectin expression. Experiments were arranged similar 
to trials dealing with the influence of nHDL subclasses on ADP-induced P-selectin ex-
pression in GFP. GFP were incubated with either nHDL2 or nHDL3 (100µg/ml) and 
platelet activation was induced by different concentrations of thrombin (6.7U/ml, 
16.7U/ml, 33.3U/ml).  
Figure 8 demonstrates a dot plot obtained by detecting P-selectin positive cells in 
thrombin-stimulated GFP by means of flow cytometry. 
 
 
Figure 8: Result of an experiment. Thrombin-induced expression of P-selectin in GFP incubated 
with nHDL2 and nHDL3 (100µg/ml). 
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A: basal 
B: thrombin (16.7U/ml) 
C: thrombin (16.7U/ml) + nHDL2 (100µg/ml) 
D: thrombin (16.7U/ml) + nHDL3 (100µg/ml) 
Percentages in the upper right indicate percentage of P-selectin positive cells. 
 
The result of an experiment, where the platelet response was quite prominent, is shown 
in Figure 8. Platelet response is dependent on activatability of the platelet itself and thus 
the experiments can differ in their magnitude of reaction. Amount of P-selectin positive 
cells in thrombin-stimulated GFP differs due to varying constituents added. Both nHDL 
subclasses impair thrombin-induced P-selectin expression (C, D) and it is shown that 
nHDL2 (C) inhibit this P-selectin expression more potent than nHDL3 (D). This is evi-
dent by comparing nHDL2 (C) and nHDL3 (D) with GFP without any nHDL (B). 
 
Data of results of 30 experiments are outlined in Figure 9. It shows the effects of nHDL2 
and nHDL3 on thrombin-induced P-selectin expression in GFP.  
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Figure 9: Influence of nHDL2 and nHDL3 (100µg/ml) on thrombin-induced expression of P-
selectin in GFP (HDL from 19 donors, n=30). 
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 nHDL2 (100µg/ml) nHDL3 (100µg/ml) 
 Mean ± SD Mean ± SD 
  6.7U/ml thrombin 84.0 ± 10.7 76.2 ± 11.2 
16.7U/ml thrombin 80.3 ± 12.9 85.2 ± 9.8 
33.3U/ml thrombin 82.2 ± 12.6 88.5 ± 11.8 
Table 8: According to Figure 9 - mean values and standard deviations of results of thrombin-
induced expression of P-selectin in GFP incubated with nHDL2 and nHDL3 (100µg/ml). 
 
In Figure 9, thrombin-induced expression of P-selectin in GFP without any nHDL is 
shown as control and set 100%. Changes of P-selectin expression in GFP with different 
nHDL subclasses are shown in relation to control. Both subclasses exhibit inhibiting 
effects on thrombin-induced P-selectin expression. nHDL2 appear to have a stronger 
impact on decreasing P-selectin expression induced by 16.7U/ml and 33.3U/ml throm-
bin than nHDL3. At a concentration of 6.7U/ml thrombin, nHDL3 seem to inhibit throm-
bin-induced platelet activation more effectively than nHDL2. Findings differ within di-
verse concentrations of thrombin.  
 
8.1.4 Influence of nHDL2 and nHDL3 on collagen-induced P-selectin 
surface expression 
The effects of nHDL2 and nHDL3 on collagen-induced P-selectin expression were ex-
amined within several experiments. An incubation of GFP with either nHDL2 or nHDL3 
(100µg/ml) was performed. Subsequently P-selectin expression in GFP was induced by 
different concentrations of collagen (40µg/ml, 50µg/ml, 100µg/ml). 
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Figure 10: Influence of nHDL2 and nHDL3 (100µg/ml) on collagen-induced expression of P-
selectin in GFP (HDL from 9 donors, n=15). 
 
 nHDL2 (100µg/ml) nHDL3 (100µg/ml) 
 Mean ± SD Mean ± SD 
  40µg/ml collagen 80.4 ± 10.5 85.2 ± 11.2 
  50µg/ml collagen 81.6 ± 10.4 88.2 ± 18.3 
100µg/ml collagen 65.9 ± 18.2 70.2 ± 21.9 
Table 9: According to Figure 10 - mean values and standard deviations of results of collagen-
induced expression of P-selectin in GFP incubated with nHDL2 and nHDL3 (100µg/ml). 
 
As indicated in Figure 10, collagen-induced expression of P-selectin in GFP without any 
nHDL is again set 100%. Collagen-induced P-selectin expression in GFP in the pres-
ence of different HDL subclasses is shown in relation to control and was quantified to 
determine the degree of platelet activation. Both nHDL subclasses exhibit inhibiting 
properties on platelet activation. GFP incubated with nHDL2 consistently impair colla-
gen-induced P-selectin expression more effectively than GFP incubated with nHDL3. 
During this study, the only platelet agonist that yielded continuous similar results at all 
concentrations added, was collagen. 
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8.2 Analytics of native and hypochlorite modified HDL2 and 
HDL3 
8.2.1 Quantification of free amino groups 
Number of free amino groups was determined by measurement of fluorescence of fluo-
rescamin (7.8) to identify differences between native and hypochlorite modified HDL 
and to further characterize their subclasses.  
We employed two strategies with regard to degree of hypochlorite modification of 
HDL. Within the first strategy, HDL2 and HDL3 were oxidized maximal (7.3), which 
implies that hypochlorite was added until optically evident bleaching of lipoproteins. 
This bleaching represents the disappearing of antioxidants in lipoproteins and the 
amount of antioxidants in the lipid phase of lipoproteins can vary. So the amount of 
hypochlorite added and therefore the modification of lipoproteins could differ from each 
other. 
Within the second strategy, HDL2 and HDL3 were adjusted to identical protein concen-
trations. This adjustment was performed by addition of PBS. So HDL2 and HDL3 of the 
same donor were modified by the same excess of hypochlorite per mg protein. Hyp-
OxHDL emerging from both hypochlorite modification strategies were used in experi-
ments at a concentration of 100µg/ml. 
 
 
Mean ± SD 
nHDL2 100% 
nHDL3 100% 
hyp-OxHDL2 13.5% ± 5.4 
hyp-OxHDL3 12.5% ± 5.9 
hyp-OxHDL2 (ident. hyp.) 8.7% ± 1.1 
hyp-OxHDL3 (ident. hyp.) 3.6% ± 1.6 
Table 10: Number of free amino groups in nHDL and hyp-OxHDL (HDL from 5 donors, n=7). 
 
As shown in Table 10, nHDL are set 100% to see the decline in the number of free 
amino groups in hyp-OxHDL in comparison to nHDL. Number of free amino groups in 
hyp-OxHDL subclasses is much lower than in nHDL subclasses because of hypochlo-
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rite modification. Number of free amino groups is almost the same in hyp-OxHDL2 and 
in hyp-OxHDL3. Moreover, results from experiments with hyp-OxHDL modified by 
identical excess of hypochlorite show that number of free amino groups in hyp-OxHDL2 
is again higher than in hyp-OxHDL3. 
 
8.2.2 Quantification of chloramines 
Chloramines emerge from reaction of chlorine with amino groups. Differences between 
native and hypochlorite modified HDL2 and HDL3 were evaluated by photometrical 
detection of chloramines (7.9).  
 
 HDL2 HDL3 
  Mean ± SD  Mean ± SD 
hyp-OxHDL 29.6 ± 6.5 35.3 ± 7.3 
nHDL 0 0 
Table 11: Content of chloramines per HDL (HDL from 5 donors, n=7). 
 
Table 11 shows content of chloramines per nHDL and per hyp-OxHDL subclasses. In-
crease of chloramines in hyp-OxHDL3 is higher than in hyp-OxHDL2. Trials were also 
carried out with hyp-OxHDL (ident. hyp.) as used in 8.2.1 and show similar results 
(data not shown) as for hyp-OxHDL. Findings indicate an obvious increase of chlor-
amines in hyp-OxHDL compared to nHDL. 
 
8.3 Experiments with hypochlorite modified HDL2 and HDL3 
Due to oxidative modification of lipoproteins in the body it is regarded as important to 
investigate the influences of modified HDL on platelet function. It is established that 
oxidized LDL show platelet-activating properties. Hypochlorite as a potent in vivo oxi-
dant (5.3.8.1) was used for modification of HDL. ADP-, thrombin-, and collagen-
induced P-selectin surface expression was quantified to determine level of platelet acti-
vation and further to verify loss of inhibiting functions of HDL in the course of oxida-
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tive modification by hypochlorite (Assinger et al. 2008). Inhibiting properties of nHDL 
on platelet degranulation of P-selectin are shown in 8.1.2, 8.1.3 and 8.1.4.  
 
8.3.1 Influence of hyp-OxHDL2 and hyp-OxHDL3 on ADP-induced ex-
pression of P-selectin 
This set of experiments was carried out to detect differences in hypochlorite modified 
HDL subclasses with regard to their effects on ADP-induced P-selectin expression in 
GFP. Results of experiments with nHDL2 and nHDL3 show inhibiting effects on ADP-
induced P-selectin expression (8.1.2) but reveal no great varieties between these sub-
classes. It is of importance to evaluate if results obtained by trials with nHDL are simi-
lar to results gained by hypochlorite modified HDL subclasses concerning their influ-
ences on ADP-induced P-selectin expression. Hyp-OxHDL2 and hyp-OxHDL3 
(100µg/ml) were incubated with GFP and P-selectin expression was induced by differ-
ent concentrations of ADP (1.7µM, 4.2µM, 8.3µM).  
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Figure 11: Influence of hyp-OxHDL2 and hyp-OxHDL3 (100µg/ml) on ADP-induced P-selectin 
expression in GFP (HDL from 9 donors, n=16). 
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 hyp-OxHDL2 (100µg/ml) hyp-OxHDL3 (100µg/ml) 
 Mean ± SD Mean ± SD 
1.7µM ADP 145.8 ± 38.1 108.4 ± 30.3 
4.2µM ADP 145.4 ± 38.7 109.2 ± 34.9 
8.3µM ADP 142.8 ± 43.5 114.3 ± 39.8 
Table 12: According to Figure 11 - mean values and standard deviations of results of ADP-
induced expression of P-selectin in GFP incubated with hyp-OxHDL2 and hyp-OxHDL3 
(100µg/ml). 
 
Figure 11 shows ADP-induced P-selectin surface expression in GFP without any HDL 
as control and is set 100%. ADP-induced P-selectin expression in GFP incubated with 
hyp-OxHDL2 or hyp-OxHDL3 is expressed relative to control. Both hyp-OxHDL sub-
classes demonstrate platelet-activating effects. Hyp-OxHDL2 indicate stronger inducing 
effects on platelet activation than hyp-OxHDL3. The loss of inhibiting properties of hyp-
OxHDL2 and hyp-OxHDL3 in contrast to nHDL2 and nHDL3 on platelet activation 
could be detected. 
 
Two strategies of hypochlorite modification of HDL, which were already used in 8.2.1 
and 8.2.2, were also adopted to the following experiments. These trials (Figure 12) were 
arranged with hyp-OxHDL subclasses (ident. hyp.), which were incubated with GFP 
and platelet activation was induced by different concentrations of ADP (1.7µM, 4.2µM, 
8.3µM) to determine their influences on P-selectin expression. 
 
 59 
0
40
80
120
160
200
1.7µM 4.2µM 8.3µM
ADP
%
 
P-
se
le
ct
in
 
po
si
tiv
e 
ce
lls
control
hyp-OxHDL-2 (100µg/ml)
hyp-OxHDL-3 (100µg/ml)
 
Figure 12: Influence of hyp-OxHDL2 and hyp-OxHDL3 (ident. hyp.) on ADP-induced P-selectin 
expression in GFP (HDL from 3 donors, n=3). 
 
 hyp-OxHDL2 (100µg/ml) hyp-OxHDL3 (100µg/ml) 
 Mean ± SD Mean ± SD 
1.7µM ADP 166.9 ± 28.1 108.5 ± 12.1 
4.2µM ADP 154.1 ± 19.6 107.2 ± 2.8 
8.3µM ADP 153.3 ± 26.9 104.8 ± 7.6 
Table 13: According to Figure 12 - mean values and standard deviations of results of ADP-
induced expression in GFP incubated with hyp-OxHDL2 and hyp-OxHDL3 (ident. hyp.). 
 
Figure 12 indicates GFP without hyp-OxHDL (ident. hyp.) as 100%, which represent 
the control. GFP incubated with either hyp-OxHDL2 or hyp-OxHDL3 (ident. hyp.) are 
shown relative to control. nHDL acquire platelet-activating properties through oxidation 
process indicated by higher percentages of P-selectin positive cells in GFP incubated 
with hyp-OxHDL2 and hyp-OxHDL3 (ident. hyp.) compared to control. Hyp-OxHDL2 
(ident. hyp.) augment ADP-induced P-selectin expression more effectively than hyp-
OxHDL3 (ident. hyp.). 
 
Figure 11 shows effects of hyp-OxHDL subclasses oxidized by the first strategy of hy-
pochlorite modification that are comparable to effects of hyp-OxHDL subclasses (ident. 
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hyp.) from the second strategy (Figure 12) on ADP-induced P-selectin expression in 
GFP. Hyp-OxHDL2 again increase ADP-induced platelet activation more effectively 
than hyp-OxHDL3. Data are consistent at all three concentrations of ADP.  
 
8.3.2 Influence of hyp-OxHDL2 and hyp-OxHDL3 on thrombin-induced 
expression of P-selectin 
Experiments were aimed at investigating differences between the subclasses hyp-
OxHDL2 and hyp-OxHDL3 in their effects on thrombin-induced P-selectin expression in 
GFP. GFP were provided with either hyp-OxHDL2 or hyp-OxHDL3 (100µg/ml) and 
platelet activation was induced by thrombin (6.7U/ml, 16.7U/ml, 33.3U/ml). 
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Figure 13: Influence of hyp-OxHDL2 and hyp-OxHDL3 (100µg/ml) on thrombin-induced P-
selectin expression in GFP (HDL from 6 donors, n=11). 
 
 61 
 hyp-OxHDL2 (100µg/ml) hyp-OxHDL3 (100µg/ml) 
 Mean ± SD Mean ± SD 
  6.7U/ml thrombin 174.4 ± 89.7 115.4 ± 33.4 
16.7U/ml thrombin 178.2 ± 81.7 116.2 ± 32.0 
33.3U/ml thrombin 156.2 ± 56.6 103.4 ± 35.7 
Table 14: According to Figure 13- mean values and standard deviations of results of thrombin-
induced expression in GFP incubated with hyp-OxHDL2 and hyp-OxHDL3 (100µg/ml). 
 
As shown in Figure 13, GFP without hyp-OxHDL represent the control and therefore 
are set 100%. Thrombin-induced P-selectin surface expression in GFP coincubated with 
different hyp-OxHDL subclasses is shown in relation to control. Hyp-OxHDL2 and hyp-
OxHDL3 exhibit platelet-activating properties indicated by higher percentages of P-
selectin positive cells compared to control. Platelet-activating effects are again more 
pronounced with hyp-OxHDL2. These findings were already identified by experiments 
dealing with the influence of hyp-OxHDL subclasses on ADP-induced expression of P-
selectin. 
 
8.3.3 Influence of hyp-OxHDL2 and hyp-OxHDL3 on collagen-induced 
expression of P-selectin 
To determine differences in hyp-OxHDL subclasses, hyp-OxHDL2 and hyp-OxHDL3 
were incubated with GFP and platelet activation was induced by different agonists to 
investigate the effects of hyp-OxHDL subclasses on ADP,- or thrombin-induced P-
selectin expression (ADP: Figure 11 and Figure 12, thrombin: Figure 13). This time 
stimulation of GFP was arranged with collagen (40µg/ml, 50µg/ml, 100µg/ml) to evalu-
ate influences of hyp-OxHDL subclasses (100µg/ml) on collagen-induced degranulation 
of P-selectin. 
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Figure 14: Influence of hyp-OxHDL2 and hyp-OxHDL3 (100µg/ml) on collagen-induced P-
selectin expression in GFP (HDL from 6 donors, n=13). 
 
 hyp-OxHDL2 (100µg/ml) hyp-OxHDL3 (100µg/ml) 
 Mean ± SD Mean ± SD 
40µg/ml collagen 202.1 ± 96.2 129.7 ± 44.8 
50µg/ml collagen 190.5 ± 84.5 126.1 ± 38.2 
100µg/ml collagen 178.7 ± 77.9 123.6 ± 33.1 
Table 15: According to Figure 14- mean values and standard deviations of results of collagen-
induced expression in GFP incubated with hyp-OxHDL2 and hyp-OxHDL3 (100µg/ml). 
 
As shown in Figure 14, collagen-induced P-selectin expression in GFP without any hyp-
OxHDL is used as control and is set 100%. Percentages of P-selectin positive cells in 
GFP incubated with different hyp-OxHDL subclasses are shown relative to control. 
Hyp-OxHDL2 as well as hyp-OxHDL3 reveal platelet-activating characteristics. More-
over, hyp-OxHDL2 show more potent activating effects on collagen-induced degranula-
tion of P-selectin than hyp-OxHDL3, which was also shown within experiments dealing 
with the influence of hyp-OxHDL subclasses on ADP- and thrombin-induced expres-
sion of P-selectin in GFP. 
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8.3.4 Different degrees of modification of hyp-OxHDL and their effects 
on VASP-P 
The following experiments were intended to evaluate the effects of nHDL and of HDL 
modified by hypochlorite to different degrees on PGE1-induced VASP-P in GFP. HDL 
were modified by hypochlorite to different degrees (7.3) and furthermore, max-OxHDL 
were treated with methionine (7.3) to obtain red-OxHDL. This methionine treatment 
results in elimination of lipoprotein associated chloramines and recovery of free amino 
groups. It is of interest, if biological effects of hyp-OxHDL can be reversed by elimina-
tion of chloramines. GFP were provided either with nHDL (100µg/ml) or with HDL 
modified by hypochlorite to different degrees and VASP-P was induced by PGE1 
(6.7nM, 16.7nM, 33.3nM). 
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Figure 15: Influence of HDL modified by hypochlorite to different degrees on VASP-P (HDL 
from 3 donors, n=6). 
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  control nHDL min-OxHDL 
  Mean ± SD Mean ± SD Mean ± SD 
  6.7nM PGE1 2.6 ± 1.0 3.7 ± 1.6 3.5 ± 1.6 
16.7nM PGE1 8.1 ± 4.0 12.3 ± 3.3 15.6 ± 11.9 
33.3nM PGE1 19.5 ± 7.5 24.1 ± 8.8 23.5 ± 7.7 
 
  mid-OxHDL max-OxHDL red-OxHDL 
  Mean ± SD Mean ± SD Mean ± SD 
  6.7nM PGE1 3.2 ± 2.1 4.5 ± 4.8 2.7 ± 0.6 
16.7nM PGE1 9.1 ± 4.0 14.8 ± 6.1 12.3 ± 6.6 
33.3nM PGE1 36.4 ± 6.9 17.4 ± 7.7 20.5 ± 4.5 
Table 16: According to Figure 15 - mean values and standard deviations of results of PGE1-
induced VASP-P in GFP without hyp-OxHDL (control), incubated with nHDL (100µg/ml), min-
OxHDL (100µg/ml), mid-OxHDL (100µg/ml), max-OxHDL (100µg/ml) and red-OxHDL 
(100µg/ml). 
 
Figure 15 shows influences of HDL modified by hypochlorite to different degrees, 
nHDL and red-OxHDL on PGE1-induced VASP-P in GFP. PGE1-induced VASP-P in 
GFP without any HDL is used as control. It is not possible to find a correlation between 
level of hypochlorite modification of HDL and percentage of VASP-P and additionally 
no regularity within the different modification classes is identifiable. nHDL are sup-
posed to show the highest percentage of VASP-P positive cells and max-OxHDL the 
lowest percentage of VASP-P positive cells. Nevertheless, max-OxHDL do not indicate 
significant effects and so one can not made significant conclusions about red-OxHDL, 
which was supposed to show a percentage of VASP-P positive cells as high as nHDL. 
 
8.3.5 Influence of 2-Chlorohexadecanal on platelet function 
2-ClHDA is an oxidation product of HDL associated plasmalogen and the oxidative 
cleavage of HDL is mediated by HOCl. A study shows that 2-ClHDA is able to decrease 
NO production in endothelial cells (Marsche et al. 2004) and another study 
demonstrates that 2-ClHDA takes part in neutrophil recruitment (Thukkani et al. 2002). 
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Due to its proven effects in endothelial cells we wanted to investigate the impact of 2-
ClHDA on platelet function. 
 
8.3.5.1 Influence of 2-ClHDA on platelet aggregation 
Effects of 2-ClHDA on platelet aggregation using microplate reader were determined. 
We wanted to investigate if 2-ClHDA itself is able to trigger platelet aggregation and at 
what concentration, and how 2-ClHDA influences platelet aggregation in combination 
with the platelet agonist ADP. 2-ClHDA was added to GFP in two different concentra-
tions (1µM, 2µM). GFP alone were used as control. 
 
 
Figure 16: Influence of 2-ClHDA (1µM, 2µM) on platelet aggregation induced by ADP. 
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a: control 
  b: 2-ClHDA (f.c.: 1µM) 
  c: 2-ClHDA (f.c.: 2µM) 
  d: 2-ClHDA (f.c.: 1µM) + ADP (f.c.: 50µM) 
  e: ADP (f.c.: 50µM) 
 
Figure 16 shows aggregation curves of platelets (a) after stimulation (b, c, d, e). 2-
ClHDA was applied at two different concentrations (b, c) and does not trigger platelet 
aggregation itself. 2-ClHDA in combination with ADP (d) shows virtually identical ag-
gregation response as ADP alone (e). 
 
8.3.5.2 Influence of 2-ClHDA on ADP-induced expression of P-selectin in GFP 
Experiments were aimed to determine the influence of 2-ClHDA on ADP-induced plate-
let degranulation of P-selectin and to detect eventual dose-dependent effects. GFP alone 
(control), incubated with increasing concentrations of 2-ClHDA (0.05µM, 0.1µM, 
0.5µM, 1µM) and incubated with 0.004% DMSO were stimulated by different concen-
trations of ADP (1µM, 2.5µM, 5µM) to induce P-selectin expression. 
 
0
10
20
30
40
50
60
1µM 2.5µM 5µM
ADP
%
 
P-
s
e
le
c
tin
 
po
s
iti
v
e
 
c
e
lls
control
0.05µM 2-ClHDA
0.1µM 2-ClHDA
 0.5µM 2-ClHDA
1µM 2-ClHDA
0.004% DMSO
 
Figure 17: Influence of different concentrations of 2-ClHDA and 0.004% DMSO on ADP-
induced expression of P-selectin in GFP (n=3). 
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 0.05µM 2-ClHDA 0.1µM 2-ClHDA 0.5µM 2-ClHDA 
 Mean ± SD Mean ± SD Mean ± SD 
 1µM    ADP 30.3 ± 8.1 21.7 ± 18.5 29.6 ± 6.8 
 2.5µM ADP 30.6 ± 7.4 28.5 ± 5.5 30.4 ± 9.0 
 5µM    ADP 32.8 ± 13.7 34.7 ± 7.4 38.1 ± 14.7 
 
 1µM 2-ClHDA 0.004% DMSO 
 Mean ± SD Mean ± SD 
 1µM    ADP 31.8 ± 11.2 28.6 ± 5.0 
 2.5µM ADP 30.5 ± 8.6 34.1 ± 11.6 
 5µM    ADP 38.7 ± 12.0 35.1 ± 13.3 
Table 17: According to Figure 17 - mean values and standard deviations of results of ADP-
induced expression of P-selectin in GFP incubated with the indicated concentrations of 2-ClHDA 
and 0.004% DMSO. 
 
Figure 17 demonstrates percentages of P-selectin positive cells in GFP incubated with 
different concentrations of 2-ClHDA. DMSO is also used as control, because 2-ClHDA 
was solubilised within this solvent (7.10). Incubation of GFP with 2-ClHDA at both 
concentrations results in weak effects on impairing ADP-induced P-selectin expression. 
There is a trend of 2-ClHDA towards a weak inhibition on ADP-induced P-selectin ex-
pression, but observed effects are mainly attributable to solvent DMSO. Taken together, 
2-ClHDA is not supposed to be responsible for platelet-activating properties of hyp-
OxHDL. 
 
8.3.5.3 Influence of 2-ClHDA on PGE1-induced VASP-P in GFP 
The effects of 2-ClHDA on platelet activation were already identified in 8.3.5.2, so the 
following experiments were aimed at investigating the influences of 2-ClHDA on plate-
let inhibitability by determining state of VASP-P. Effects of 2-ClHDA on PGE1-induced 
VASP-P in GFP were examined by quantification of VASP-P positive cells. GFP were 
treated with two different concentrations of 2-ClHDA (1µM, 2µM) and VASP-P was 
induced by different concentrations of PGE1 (6.7nM, 16.7nM, 33.3nM), the same pro-
cedure for GFP without 2-ClHDA and GFP incubated with 0.04% DMSO. 
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Figure 18: Influence of 2-ClHDA (1µM, 2µM) and 0.04% DMSO on PGE1-induced VASP-P in 
GFP (n= 2 / for DMSO n=1). 
 
 1µM 2-ClHDA 2µM 2-ClHDA 0.04% DMSO 
 Mean ± SD Mean ± SD Data 
  6.7nM PGE1 78.5 ± 16.3 116.1 ± 17.1 92.0 
16.7nM PGE1 195.6 ± 13.2 132.0 ± 71.0 197.1 
33.3nM PGE1 143.8 ± 1.8 159.2 ± 0.3 178.4 
Table 18: According to Figure 18 - mean values and standard deviations of results of PGE1-
induced VASP-P in GFP incubated with 2-ClHDA (1µM, 2µM) and 0.04% DMSO. 
 
PGE1-induced VASP-P in GFP without any 2-ClHDA is set 100% and used as control. 
PGE1-induced VASP-P in GFP with different concentrations of 2-ClHDA is set in rela-
tion to control. As shown in Figure 18, incubation of GFP with 2-ClHDA leads to a 
higher percentage of VASP-P positive cells than in the control, but observed effects are 
again mainly attributable to solvent DMSO. These effects do not occur at 1µM 2-
ClHDA at a concentration of 6.7nM PGE1, but sample size is too low to draw clear con-
clusions. There is a trend of 2-ClHDA towards a weak effect on increasing VASP-P.  
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8.3.5.4 Influence of nHDL subclasses pre-incubated with 2-ClHDA on ADP-
induced expression of P-selectin in GFP 
To determine effects of 2-ClHDA in combination and in interplay with nHDL on ADP-
induced P-selectin expression, nHDL2 and nHDL3 were pre-incubated with 2-ClHDA. 
Additionally we incubated GFP with nHDL2 and nHDL3 but without 2-ClHDA. 2-
ClHDA was applied at 2 different concentrations (1.27nM and 7.6nM 2-ClHDA) to 
GFP (7.6.2).  
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Figure 19: Influence of nHDL2 and nHDL3 (100µg/ml) pre-incubated with 2-ClHDA (1.27nM, 
7.6nM) on ADP-induced P-selectin expression in GFP (n=2). 
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 nHDL2 (100µg/ml) nHDL3 (100µg/ml) 
 Mean ± SD Mean ± SD 
1.7µM ADP 47.0 ± 7.3 45.3 ± 8.1 
4.2µM ADP 54.4 ± 0.6 50.6 ± 9.7 
8.3µM ADP 56.2 ± 7.4 54.1 ± 7.8 
 
 nHDL2 (100µg/ml) + 2-ClHDA nHDL3 (100µg/ml) + 2-ClHDA 
 Mean ± SD Mean ± SD 
1.7µM ADP 29.1 ± 16.2 23.8 ± 7.3 
4.2µM ADP 29.5 ± 12.9 27.8 ± 10.8 
8.3µM ADP 33.0 ± 18.0 31.9 ± 13.9 
Table 19: According to Figure 19 - mean values and standard deviations of ADP-induced expres-
sion of P-selectin in GFP incubated with nHDL2 (100µg/ml), nHDL3 (100µg/ml), HDL2 
(100µg/ml) + 2-ClHDA and HDL3 (100µg/ml) + 2-ClHDA. 2-ClHDA was added at two different 
final concentrations (1.27nM, 7.6nM). 
 
Results of the experiments with 1.27nM and 7.6nM 2-ClHDA are at a similar level and 
are outlined in Figure 19, which shows percentages of P-selectin positive cells in GFP. 
nHDL3 inhibit platelet activation more effectively than nHDL2. nHDL2 pre-incubated 
with 2-ClHDA shows similar effects on ADP-induced platelet activation as nHDL3 pre-
incubated with 2-ClHDA. Data for nHDL2 incubated with 0.0015% DMSO (n=1) are 
74.4 at 1.7µM ADP, 80.5 at 4.2µM ADP and 82.7 at 8.3µM ADP. Data for nHDL2 incu-
bated with 0.009% DMSO (n=1) are 66.5 at 1.7µM ADP, 77.0 at 4.2µM ADP and 72.4 
at 8.3µM ADP. Experiments indicate a tendency of nHDL3 in combination with 2-
ClHDA to stronger inhibiting effects on ADP-induced P-selectin expression than nHDL2 
incubated with 2-ClHDA. 
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9 Discussion 
Atherosclerosis is an inflammatory disease that causes a pro-oxidative environment. 
Therefore, lipoproteins in the vascular wall can be oxidized. In this scenario, HDL re-
acts as scavenger of the naturally occurring oxidant hypochlorite to protect other targets 
(e.g. LDL) from oxidative damage. The oxidative modification hypothesis says that 
oxidation of lipoproteins can be prevented by antioxidants (Jessup et al. 2004). More-
over, several studies and reviews confirm that HDL have atheroprotective effects and 
therefore diminish cardiovascular risk (Barter et al. 2003a;Buring et al. 1992;Chen and 
Mehta 1994;Mineo et al. 2006). Within this project two main strategies were pursued, 
effects of nHDL and hyp-OxHDL on platelet activation determined as P-selectin posi-
tive cells and their effects on inhibitability of platelets determined as VASP-P positive 
cells were defined. ADP-, thrombin-, and collagen-induced P-selectin surface expres-
sion as well as PGE1-induced VASP-P in platelets were quantified. P-selectin represents 
an indicator for platelet degranulation and activation, because it is stored in α-granules 
and expressed on the surface of platelets after their activation. The phosphorylation of 
VASP is an indicator for inhibition of platelets and is induced by PGE1 through an in-
crease in cAMP dependent protein kinase (5.2.3.1). Thus these methods are appropriate 
to demonstrate influences of nHDL and hyp-OxHDL on platelet function. Investigations 
of nHDL2 on PGE1-induced VASP-P were carried out to compare these effects with the 
effects from nHDL3. A dose dependency is necessary to evaluate, because then trials 
with dedicated concentrations of nHDL2 and nHDL3, whereat effects are known, can be 
carried out. Additionally, it is fundamental to know at which concentrations nHDL2 and 
nHDL3 have the lowest and the highest impact on PGE1-induced VASP-P in GFP. Re-
sults of experiments show that increasing concentrations of nHDL2 are associated with 
rising percentages of VASP-P positive cells. Similar investigations were made for 
nHDL3, which fail to show dose-dependent effects on PGE1-induced VASP-P. Data re-
sulting from experiments with nHDL3 on PGE1-induced VASP-P were compared to data 
obtained by experiments with nHDL2 at defined concentrations (50µg/ml, 100µg/ml, 
150µg/ml). nHDL2 and nHDL3 do not vary much at concentrations of 50µg/ml and 
100µg/ml in their effects on PGE1-induced VASP-P. At a concentration of 150µg/ml, 
nHDL3 increase VASP-P more effectively than nHDL2. But due to high standard devia-
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tions, data are not significant. The influence of nHDL subclasses on ADP-, thrombin-, 
and collagen-induced P-selectin expression was also determined. Simply at collagen-
induced P-selectin expression in GFP, nHDL2 have continually stronger inhibiting ef-
fects on P-selectin expression at all collagen concentrations. Both nHDL subclasses 
decrease agonist-induced P-selectin expression and therefore inhibit platelet activation. 
Moreover, other findings show that thrombin-induced platelet aggregation is decreased 
by HDL (Aviram and Brook 1983). Researchers suggest that most of the inhibiting ef-
fects of nHDL on platelet aggregation are situated in the HDL2 fraction due to their con-
tent of apo-E (Desai et al. 1989). Further studies show that nHDL2 inhibit collagen-, and 
thrombin-induced platelet aggregation more effectively than nHDL3. Apo-E rich HDL 
from hyperalphalipoproteinemic subjects with plasma cholesteryl ester transfer protein 
deficiency exhibit more inhibiting effect on agonist-induced platelet aggregation than 
nHDL from normal donors (Higashihara et al. 1991b). Furthermore, researchers found 
that purified apo-E (10-50µg/ml), complexed with phospholipid vesicles (DMPC) di-
minish platelet aggregation induced by ADP, adrenaline, or collagen (Riddell et al. 
1997). Thrombin-induced platelet aggregation is suppressed by apo-E DMPC in a dose 
dependent manner (Higashihara et al. 1991b). HDL-E, a minor subclass of HDL con-
taining apo-E, have a potent anti-platelet effect. They represent a powerful inhibitor of 
agonist-induced platelet aggregation, obviously through interaction with saturable bind-
ing sites in the platelet surface membrane (Riddell et al. 1997;Riddell and Owen 1996). 
In contrast, findings demonstrate that the inhibitory potential of nHDL on platelet ag-
gregation does not strictly depend on the presence of apo-E and that other factors 
probably play a role as well (Higashihara et al. 1991a). We have not determined the 
apolipoprotein composition of nHDL subclasses from our donors. The observed effects 
could probably be influenced by differing apolipoprotein contents. 
 
Analytical measurements were conducted to identify differences in nHDL and hyp-
OxHDL concerning their content of chloramines and the number of free amino groups. 
Content of free amino groups in hyp-OxHDL is decreased in comparison to nHDL, 
which is a result of hypochlorite modification. The first hypochlorite modification strat-
egy was performed until optically evident bleaching of lipoproteins, which indicates the 
disappearing of antioxidants in lipoproteins. Due to varying amounts of antioxidants in 
 73 
the lipid phase of lipoproteins, the amount of hypochlorite added was different. The 
second hypochlorite modification strategy was carried out with identical protein concen-
trations in HDL2 and HDL3 and so lipoproteins of the same donor were modified by the 
same excess of hypochlorite per mg protein. Results demonstrate that hyp-OxHDL2 and 
hyp-OxHDL3 do not vary much in their number of free amino groups. HDL subclasses 
modified by identical excess of hypochlorite show that the decrease in content of free 
amino groups is higher in hyp-OxHDL3 (ident. hyp.) than in hyp-OxHDL2 (ident. hyp.). 
Free amino groups are converted into chloramines through oxidation process. A reason 
for the greater decrease of free amino groups in hyp-OxHDL3 could be that apoA-I is a 
major apolipoprotein component of HDL3 and is a favored target for hypochlorite modi-
fication (Panzenboeck et al. 1997). The content of apoA-I and apoA-II is differing in 
HDL2 and HDL3 and we speculate that apoA-I and apoA-II are oxidized in a different 
way and speed. Another trial performed was the determination of chloramines in nHDL 
and hyp-OxHDL. Chloramines are increased in hyp-OxHDL compared to nHDL. The 
modification procedure by hypochlorite results in enhanced content of chloramines, 
which was also observed for LDL by Plass et al. (Plass et al. 2007). We are able to 
demonstrate that hypochlorite modification decreased content of free amino groups and 
increased content of chloramines in both hyp-OxHDL subclasses. 
 
Oxidative modification of HDL2 and HDL3 was performed by sodium hypochlorite, 
which is formed from H2O2 by MPO in the presence of physiological chloride concen-
trations. HDL are a selective in vivo target for MPO catalyzed oxidation. MPO has in 
vivo relevance, which is confirmed by its occurrence in human lesion material and 
seems to be linked to HDL extracted from human atheroma (Malle et al. 2006b). Re-
sults of studies show that atheroprotective properties of nHDL may disappear as a result 
of their oxidative modification by oxidants generated by MPO (Nicholls et al. 2005). 
The loss of inhibiting properties of nHDL on platelet activation and aggregation in the 
course of oxidation by hypochlorite is already known. Furthermore, hyp-OxHDL are 
able to trigger platelet aggregation so that HDL are converted into an independent plate-
let activator (Assinger et al. 2008). The influence of hyp-OxHDL2 and hyp-OxHDL3 on 
ADP-, thrombin-, and collagen-induced P-selectin expression in GFP was also evalu-
ated. Hyp-OxHDL2 increase agonist-induced P-selectin expression more effectively 
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than hyp-OxHDL3. Quantification of PGE1-induced VASP-P in GFP incubated with 
HDL modified by hypochlorite to different degrees was also arranged. Surprisingly, 
VASP-P in GFP incubated with hyp-OxHDL increased. Freedman et al. detected that a 
large amount of NO is released shortly after activation to prevent further aggregation. 
The endothelial cell production of NO impedes partially adhesion of platelets to the 
vessel wall and NO inhibits platelet aggregation (Freedman et al. 1997). This can possi-
bly be a cause for enhanced VASP-P by hyp-OxHDL. 
 
Additionally, attempts to evaluate the impact of 2-ClHDA on platelet degranulation of 
P-selectin and VASP-P were made. HOCl mediated cleavage of plasmalogen, which is 
associated with HDL, results in formation of 2-ClHDA. The importance of 2-ClHDA is 
shown in studies, which suggest its potential to modulate and inhibit eNOS expression 
and activity in endothelial cells (Marsche et al. 2004). 2-ClHDA probably also plays a 
role in neutrophil recruitment, where it has inducing effects at physiologically relevant 
concentrations (Thukkani et al. 2002). It may have an impact on vascular injury, glome-
rulosclerosis, and atherosclerosis (Marsche et al. 2004). The hypothesis that 2-ClHDA 
might show an influence on platelet aggregation was tested by determining light trans-
mission in microplate reader. GFP incubated with 2-ClHDA show unaltered ADP-
induced aggregation response and 2-ClHDA does not trigger platelet aggregation itself. 
Trials dealing with the influence of 2-ClHDA on ADP-induced P-selectin expression in 
GFP show a tendency of 2-ClHDA to inhibiting effects on platelet activation, but sam-
ple size was too small to draw clear conclusions. However, 2-ClHDA is also able to 
increase PGE1-induced VASP-P in GFP. 2-ClHDA in combination with nHDL3 inhibit 
ADP-induced P-selectin expression more effectively than 2-ClHDA combined with 
nHDL2.  
 
9.1 Outlook 
Results of experiments demonstrate that incubation of GFP with hyp-OxHDL leads to 
increased percentages of VASP-P (8.3.4). These results are contrary to findings that 
demonstrate platelet-activating properties of hyp-OxHDL (8.3.1, 8.3.2, 8.3.3). Hence we 
expected that hyp-OxHDL decrease PGE1-induced VASP-P. One explanation for this 
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contrast could be that a large amount of NO is released shortly after activation to pre-
vent further aggregation (Freedman et al. 1997). L-arginine is required for NO synthesis 
and through L-arginin analoga, L-NAME, L-NMMA, respectively it is possible to block 
this NO synthesis (Freedman et al. 1997). Future trials can thus be using such analoga, 
so that an increase of VASP-P due to release of NO as a result of platelet aggregation 
can not emerge. So falsification of results evoked by this mechanism will not be possi-
ble.  
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10 Summary 
This diploma thesis was aimed at investigating the effects of native and modified high 
density lipoproteins (subclass 2 and 3) on platelet function such as activation state, de-
termined as expression of P-selectin, and inhibitability of platelets, measured as intra-
cellular degree of VASP phosphorylation.  
Both nHDL subclasses exhibited inhibiting properties on agonist-induced P-selectin 
expression, but no significant differences between nHDL2 and nHDL3 were found. Only 
at collagen-induced P-selectin expression nHDL2 impaired platelet activation more ef-
fectively than nHDL3. Furthermore, nHDL were able to increase PGE1-induced VASP-
P, but again no significant varieties in nHDL subclasses were shown. However, nHDL3 
(150µg/ml) showed more platelet-inhibiting properties compared to nHDL2 (150µg/ml). 
These findings affirm atheroprotective effects of nHDL. 
Moreover, experiments with hypochlorite modified HDL were carried out. Results re-
vealed that both hyp-OxHDL subclasses are able to enhance agonist-induced P-selectin 
expression in platelets. Thus it was shown that nHDL acquire platelet-activating proper-
ties through oxidation process. Hyp-OxHDL2 showed more potent platelet-activating 
effects than hyp-OxHDL3. HDL modified by hypochlorite to different degrees showed 
the trend towards increasing VASP-P. 
A strong decrease in free amino groups as well as an increase in chloramines in hyp-
OxHDL compared to nHDL was shown.  
The influence of the oxidation product 2-ClHDA on platelet function was analyzed as 
well. 2-ClHDA did not trigger platelet aggregation itself and indicated weak effects with 
regard to an inhibition of P-selectin expression induced by ADP and to an enhancement 
in VASP-P induced by PGE1. 
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11 Zusammenfassung 
Ziel dieser Diplomarbeit war Einflüsse von nativen und modifizierten Lipoproteinen 
hoher Dichte (Unterklasse 2 und 3) auf den Aktivierungszustand von humanen Throm-
bozyten, gemessen als Expression von P-Selektin, und auf die Hemmbarkeit, gemessen 
als Phoshorylierung von VASP, zu untersuchen.  
Native HDL Unterklassen zeigten dosisabhängige sowie hemmende Effekte auf die 
Thrombozytenaktivierung, die durch verschiedene Agonisten (ADP, Thrombin, Kolla-
gen) induziert wurde, wobei keine signifikanten Unterschiede zwischen den HDL Un-
terklassen festgestellt werden konnten. Nur bei einer von Kollagen induzierten Throm-
bozytenaktivierung offenbarten nHDL2 eine stärker hemmende Wirkung auf die 
Expression von P-Selektin als nHDL3. Weiters führten beide nHDL Unterklassen zu 
einer Erhöhung der VASP-Phosphorylierung, wobei nHDL3 bei einer Konzentration 
von 150µg/ml stärker steigernd wirkten als nHDL2. Dadurch konnte eine erhöhte 
Hemmbarkeit der Thrombozyten gezeigt und die atheroprotektiven Effekte von nHDL 
bestätigt werden. 
Zusätzlich wurden Versuche mit Hypochlorit modifizierten HDL durchgeführt, welche 
eine durch Agonisten induzierte Thrombozytenaktivierung verstärkten, wobei hyp-
OxHDL2 eine größere stimulierende Wirkung als hyp-OxHDL3 zeigte. Hiermit konnte 
bestätigt werden, dass nHDL durch Oxidation Thrombozyten aktivierende Eigenschaf-
ten erlangen. Die VASP-Phosphorylierung wurde von unterschiedlich modifizierten 
HDL erhöht. 
Weiters wurde ein starker Rückgang von freien Aminogruppen sowie ein Anstieg an 
Chloraminen in hyp-OxHDL verglichen mit nHDL festgestellt.  
Darüber hinaus wurde der Einfluss von 2-Chlorohexadekanal auf die Thrombozyten-
funktion untersucht. Zum einen wirkte es schwach inhibierend auf eine durch Agonisten 
induzierte Thrombozytenaktivierung und zum anderen führte es zu einer erhöhten 
Hemmung der Thrombozyten. Dieses Oxidationsprodukt hat weiters selbst keine Ag-
gregation der Thrombozyten hervorgerufen und eine ADP-induzierte Agreggation nicht 
verändert. 
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12 Abbreviations 
ABCA1:   ATP binding cassette A1 
ADP:   adenosine diphosphate 
cAMP:   cyclic adenosine monophosphate 
CEPT:   cholesteryl ester transfer protein 
CEs:    cholesteryl esters 
CHD:   coronary heart disease 
cGMP:   cyclic guanosine monophosphate 
DMPC:   dimyristoylphoshatidylcholine 
DMSO:  dimethyl sulfoxide 
FACS:   fluorescent activated cell sorting  
f.c.:    final concentration 
GFP:   gel filtered platelets 
GP:    glycoprotein 
HDL:   high density lipoproteins 
HDL2:   high density lipoproteins subclass 2 
HDL-2:   high density lipoproteins subclass 2 
HDL3:   high density lipoproteins subclass 3 
HDL-3:   high density lipoproteins subclass 3 
HOCl:  hypochlorous acid 
hyp-OxHDL:  hypochlorite modified high density lipoprotein 
ident. hyp.:  identical excess of hypochlorite added 
kDa:    kilo dalton 
LCAT:   lecithin cholesterol acyltransferase 
LDL:   low density lipoproteins 
MI:    myocardial infarction 
MPO:   myeloperoxidase 
NADPH:   nicotinamide adenine dinucleotide phosphate 
NaOCl:   sodium hypochlorite 
nHDL:   native high density lipoproteins 
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NIDDM:   non insulin dependent diabetes mellitus 
NO:    nitric oxide 
NOS:   nitric oxide synthase 
OCl-:   hypochlorite 
PAR:   protease activated receptor 
PGE1:   prostaglandin E1 
PGE2:   prostaglandin E2 
PGI2:   prostaglandin I2 = prostacyclin 
PI3-kinase:  phosphoinositide kinase 
PPARα:   peroxisome proliferator- activated receptor alpha 
PRP:   platelet rich plasma 
ROS:   reactive oxygen species 
SR-B1:   scavenger receptor type B1 
TG:    triglycerides 
TXA2:   thromboxane 
VASP:   vasodilator-stimulated phosphoprotein 
VASP-P:   phosphorylated VASP 
VLDL:   very low density lipoproteins 
vWf :   von Willebrand factor 
2-ClHDA:   2-Chlorohexadecanal 
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